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By 
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India 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor 
of Philosophy at Virginia Commonwealth University. 
Virginia Commonwealth University, 2008 
 
      MDM2, the human homologue of the Mouse Double Minute 2 gene product, has been 
shown to be over-expressed in many cancers and to induce tumorigenesis. The role of 
MDM2 in oncogenesis was thought to be p53 dependent. However recent years have 
shown MDM2 to be a key player in a complex network of interactions that affect cell 
cycle, apoptosis, and tumorigenesis in a p53 independent manner. Here we report a novel 
p53 independent role for the multidimensional protein MDM2; its ability to induce 
phosphorylation of Akt at serine 473 residue. Transient and stable over-expression of 
MDM2 in cultured cell lines induces Akt phosphorylation. Silencing of MDM2 expression 
in cancer cells that over express MDM2 inhibits Akt phosphorylation suggesting 
endogenous MDM2 participates in Akt phosphorylation. Stable up-regulation of MDM2 
expression reduced sensitivity of cells to chemotherapeutic drugs such as Etoposide, 
  
Carboplatin or Paclitaxel. The domain of MDM2 responsible for drug resistance overlaps 
with the Akt phosphorylation domain. An inhibitor of Akt phosphorylation abrogated 
MDM2-mediated Akt phosphorylation and reduction of Etoposide sensitivity indicating 
that MDM2 reduces Etoposide sensitivity of cancer cells by activating the Akt 
phosphorylation. A PI-3 kinase inhibitor Wortmannin inhibits the ability of MDM2 to 
induce Akt phosphorylation and silencing of Rictor, a known kinase of Akt, does not 
hamper the ability of MDM2 to induce phosphorylation of Akt. MDM2-mediated Akt 
phosphorylation does not require p53, and the p53-interaction domain of MDM2 is 
dispensable for Akt phosphorylation. The presence of MDM2 enhances the Insulin like 
Growth Factor 1 mediated activation of Akt. Further cells harboring MDM2 show 
enhanced Interleukin 8( IL8) activation, which could be a possible mechanism of Akt 
activation.  Downstream of Akt activation we show increased events that have been 
correlated with Akt activation like increased Bcl-2 levels increased processing of NF-κB2, 
and GSK3α/β phosphorylation among others. Our observation reveals a novel signaling 
function of MDM2 important for regulation of cell growth and chemotherapeutic 
sensitivity through Akt phosphorylation.   
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H. Chapter 1.Introduction 
MDM2 is potentially oncogenic:  Cancer is a group of diseases whose defining factor is 
uncontrolled growth of abnormal cells, which can metastasize- a process whereby the cells 
grow beyond their normal boundaries and spread to distant parts of the body. According to 
the WHO, in 2007 alone, Cancer accounted for nearly 7.9 million deaths (around 13% of 
all deaths) worldwide.  
 The human homologue of the murine double minute-2 gene product (MDM2) is weakly 
expressed in normal cells. But it is over-expressed in many human carcinomas, soft tissue 
sarcomas and other cancers, suggesting that the genetic alteration may be an important 
contributor to oncogenesis and disease progression(1-15). Over-expression of MDM2 has 
been shown to enhance tumorigenic potential of murine cells(16,17). Targeted tissue 
specific expression of MDM2 in transgenic mice causes polyploidy(18) . Over-expression 
of MDM2 in breast epithelial cells inhibits normal development of mammary gland 
(18)and targeted over-expression in the basal layer of epidermis increases papilloma 
formation by chemical carcinogens(19). Amplification of mdm2 gene, Over-expression of 
mdm2 mRNA(4,10,20,21) and enhanced translation of the mdm2 mRNA (11,22,23)are 
proposed mechanisms of MDM2 over-expression.  
Frequency of MDM2 amplification: MDM2 is found in very low amounts in normal 
cells. However the overall frequency of MDM2 amplification in both benign and 
malignant tumors is about 7%. 20% of all soft tissue tumors which include Ewing’s 
sarcoma(13), leiomyosarcomas(24-26), lipomas(25,27), liposarcomas, malignant fibrous 
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histiocytomas(20,24,27-29), malignant schwannomas(20,24,25,27,30) and other sarcomas 
such as rhabdomyosarcomas(31)  have MDM2 amplication. 16% of all osteosarcomas 
have MDM2 amplification(12,20,24,27).Roughly 10% of all gliomas over express 
MDM2(8,32-34). MDM2 over-expression has also been reported in about 13% of lung 
carcinomas, breast cancers and testicular cancers(15). 
MDM2 as a prognostic marker: Though over-expression of MDM2 is a common event 
in cancer, as a prognostic marker it presents a paradox. Over-expression of MDM2 
correlates with poor prognosis in sarcomas, breast cancers and lymphomas(32,35) and with 
good prognosis in lung carcinoma, malignant melanoma and ovarian cancer(3,36-39). This 
is further complicated by the co-occurrence or lack of p53 expression. Among soft tissue 
sarcomas, it was noticed that cases with mutant p53 and MDM2 expression had the worst 
prognosis, suggesting a Wild Type (WT) p53 independent oncogenic role for MDM2. 
Patients lacking both p53 and MDM2 had the best prognosis. In gliomas, where MDM2 is 
found over-expressed in nearly 10% of all cases, p53 mutations rarely co-occur with 
MDM2 over-expression. And in pediatric acute lymphoblastic leukemia, loss of WTp53 is 
a very rare event, though MDM2 mRNA over-expression has been shown to correlate with 
poor prognosis(32). Therefore tissue specific, differentiation specific and growth specific 
pressures exist, to which the different tumor subsets respond in different ways. 
MDM2 and p53: The mdm2 gene product was originally detected in a complex with p53 
(40). This association has been the most studied and the interaction has been found to be 
involved in an auto regulatory feedback loop. MDM2 can recognize the transactivation 
domain of p53 and thus inactivate the p53 mediated transcriptional activation. This 
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interaction has been shown both in vivo and in vitro. MDM2 is an E3 ubiquitin ligase and 
following binding to p53, it can target p53 for ubiquitination. For the ubiquitination 
function, MDM2 employs the RING finger domain for mono ubiquitination and the p300 
interaction domain for poly ubiquitination.  It is important to note the mutants of MDM2 
lacking the ubiquitin ligase domain can bind to p53 and inhibit p53 mediated 
transcriptional activation(41-44).  Therefore inhibition of transactivation and degradation 
of p53 are probably two distinct ways to regulate p53. (20, 40, 45-51). Also MDM2 
ubiquitinates itself and thus regulates its expression.(52) MDM2 can be transcriptionally 
activated by p53 (20,40,45-51). The MDM2 gene has two distinct promoters and p53 
mediated activation from the P2 promoter yield a distinct splice transcript differing in the 
5’ untranslated region from the P1 promoter product. (53). 
MDM2 interactions: MDM2 interacts with a gamut of proteins in vivo.  Consistent with 
its oncogenic potential, MDM2 interacts with several known growth suppressors, including 
p53, the p53 family protein p73(54), the retinoblastoma susceptibility gene product Rb(55) 
and growth suppressor p14 ARF (56,57)and p19(58,59). MDM2 has ben shown to interact 
with histones and histone deacetylases(60). It has been shown to interact with ribosomal 
proteins(54). Other MDM2 partners include, the p53 coactivator p300(61), the p53 co-
regulator MDMX(62), the transcription factors E2F1/DP1(63) and SP1(64),mutant 
p53(65), cell fate protein NUMB(66) and the ribosomal protein L5(54). Mayo et al showed 
that after growth factor stimulation MDM2 interacts with Akt and gets phosphorylated, 
thus linking the mitogenic signaling pathway and MDM2(67). Later studies by various 
groups showed that MDM2 was able to ubiquitinate components of the mitogenic 
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signaling pathway including IGF1-R(68), β Arrestins(69) and G protein coupled Receptor 
Kinase 2(GRK2)(70).                                                                                                                                             
 
 
 
 
P53 independent activities of MDM2: Though most of the initial studies on MDM2 
extensively characterized MDM2 as a p53 regulator, there is increasing evidence of p53 
independent activities of MDM2. Transgenic mice with full length MDM2 are predisposed 
to spontaneous tumor formation in a p53-/- background and have a high incidence of 
lymphoma and sarcoma.(71) The interactions of MDM2 with factors which function as 
regulators in processes like transformation, cell cycle control, DNA synthesis, RNA 
biosynthesis, transcription, mitogenic signaling pathways can happen in a p53 null 
environment(54). 
Figure 1. MDM2 interacting proteins: The domains of MDM2 where it binds to its 
interacting partners are shown by the black lines. MDM2 has many interacting partners in the 
cell, involved in a wide range of functions. These include cell cycle, tumorigenesis, 
differentiation, DNA synthesis, DNA repair, RNA biosynthesis, Transcription among others. 
 16 
 
MDM2 has been shown to confer growth advantage in cells devoid of p53 and pRb(72). 
Increased MDM2 expression has been shown to correlate with TGF-β resistance in human 
breast tumor cells independent of p53 status contributing to tumorigenesis(73). 
Amplification of MDM2 was found to interfere with MyoD activity in rhabdomyosarcoma, 
thus inhibiting overt muscle differentiation independent of p53(74). Numb, a cell fate 
protein involved in neural cell differentiation is a binding parter of MDM2 and gets 
ubiquitinated by MDM2(75). MDM2 can form a complex with pRb in vivo and blocks 
pRb mediated G1 arrest(55). MDM2 can also interact with E2F/DP1 transcription factor 
involved in S-phase progression(63). Yeast 2-hybrid screens and in vivo co-
immunoprecipitations have shown MDM2 to interact with DNA Polymerase ε(76). MDM2 
has also been shown to bind to the NBS1 protein and inhibit double strand break 
repair(77).The central domain of MDM2 was shown to interact with L5, a component of 
the large ribosomal subunit independent of p53(78). MDM2’s role in transcription can be 
evidenced by its interaction with the TATA Binding Protein(79), Transcription Activating 
Factor II D(54), transcriptional co-activator p300(61) and by its ability to induce 
expression of p65(80). Recent years have shown the role of MDM2 in the rapid turnover of 
surface receptors in response to mitogenic signal activation. MDM2 has been shown by 
various groups to bind and ubiquitinate the Androgen Receptor(81),  and the Insulin like 
Growth Factor-1 Receptor( IGF-1 R)(68) and also key regulators like β arrestins (69)and G 
Protein Coupled Receptor Kinase( GRK2) (70)among others. 
MDM2 interacts with Ef1α: In order to further study the p53 independent activities of 
MDM2, our lab carried out a mass spectrometric analysis of MDM2 bound proteins in 
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H1299, non small cell lung cancer cell line which was devoid of functional p53.  Among 
the various proteins identified as potential MDM2 binding partners was the translational 
Elongation Factor (EF1α).  This result was further confirmed by immunoprecipitation 
experiments(82). EF1α was shown by various groups to activate the Phosphatidylinositol  
4 kinase(83), which in turn activated the Phosphatidylinositol 3 Kinase pathway resulting 
in activated Protein kinase B or Akt. This was shown to increase actin remodeling and 
result in increased motility(84).  
MDM2 interacts with Akt: It has been reported that MDM2 and Akt interact in the 
cytoplasm of the cell. This interaction leads to the phosphorylation of MDM2 at residues 
serine 166 and serine 186(67,85).Later Milne et al showed that amino acids 108- 200 of 
MDM2 were required for the complete phosphorylation of MDM2 by Akt and that a 
deletion mutant of MDM2 harboring amino acids196-282 was phosphorylated, but to a 
lesser extent(86). This seems to suggest that there may be two domains of MDM2 where 
Akt could bind to and phosphorylate it. Akt mediated MDM2 phosphorylation was shown 
to be required for the nuclear entry of MDM2. This facilitated the interaction of MDM2 
and p53 and subsequent degradation of p53 after ubiquitination of p53 and its nuclear 
export.  
The PI3K- Akt Pathway: The Phosphatidylinositol 3’-kinase (PI3K)-Akt signaling 
pathway regulates fundamental cellular functions such as transcription, translation, 
proliferation, growth and survival. Akt or protein kinase B is a serine/threonine kinase and 
the most important effector molecule in the pathway. The deregulation of the pathway has 
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been associated with the development of diseases such as cancer, diabetes mellitus and 
autoimmunity(87-92). 
PI3K is responsible for the phosphorylation of the 3 position of the inositol ring of 
PI(4,5)P2, to generate PI(3,4,5)P3, a potent second messenger required for survival 
signaling and insulin action(93-95). PI3K is composed of two subunits: a catalytic subunit 
p110 and a regulatory subunit p85, which is activated by receptors with protein tyrosine 
kinase activity (Receptor Tyrosine Kinase, RTK) and by G protein coupled receptors 
(GPCR). Within seconds, activated PI3K converts plasma membrane lipid PI(4,5)P2 to 
PI(3,4,5)P3 (93-96). This prompts the translocation of Akt to the inner side of plasma 
membrane and binding to the phospholipids.(93, 95) This results in a conformational 
change in Akt and subsequent exposure of its two main phosphorylation sites; Threonine 
308 and Serine 473. Activation of PI(3,4,5)P3 also allows binding of Protein serine/ 
threonine kinase 3’phosphoinositide Dependant Kinase ( PDK1) to PI(3,4,5)P3 and to Akt. 
This leads to the phosphorylation of Akt at Threonine 308 residue. For the full activation 
of Akt, the serine 473 residue needs to get phosphorylated(89,94,95,97,98). Many players 
have been identified or suspected to cause the phosphorylation at this residue. Rictor(99), 
Integrin Linked Kinase( ILK)(100-102) and Akt itself(103) are a few of these. Akt also 
gets activated in response to oxidative and osmotic stress, irradiation and treatment of cells 
to chemotherapeutic agents and ischemic shock(90). Recently it has also been shown that 
phosphorylation of Akt at serine 473 can occur in response to DNA damage and DNA 
dependant Protein Kinase ( DNA-PK) was responsible for the event(104). 
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Regulation of the Akt phosphorylation event is achieved by phosphatases which act at 
various stages along the PI3K/Akt pathway. The Phosphatase and Tensin Homologue 
deleted on chromosome 10( PTEN) is a phosphatase that can reverse the conversion of  
PI(4,5)P2 to PI(3,4,5)P3(105). PI(3,4,5) P3 can be converted to PI(3,4)P2 by the SH2 
domain-containing inositol 5-phosphatase (SHIP)(98) The phosphatases in the PHLPP 
family, PHLPP1 and PHLPP2 have been shown to directly de-phosphorylate, and therefore 
inactivate, distinct Akt isoforms(106,107). Phosphatase 2A (PP2A) is another enzyme 
involved in the dephosphorylation of Akt. (108) Another protein, the Carboxy Terminal 
Modulating Protein (CTMP) binds to the C terminus of Akt , where it dephosphorylates 
Akt(109).  
 
 
 
 
 
Figure 2. The PI3K-Akt pathway regulation: The binding of growth factors to their 
receptor tyrosine kinase (RTK) or the G Protein Coupled Receptors (GPCR) stimulate the 
phosphorylation of PI3K. Activated PI3K converts PIP2 to PIP3, whereas PTEN and SHIP 
reverse this reaction. Akt translocates to the membrane and gets phosphorylated at Threonine 
308 by PDK1. This is followed by phosphorylation at Serine 473 by kinases such as Rictor, 
ILK etc. Dephosphoylation at Serine 473 can be achieved by enzymes such as PHLPP and 
proteins like CTMP. 
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Functions of Akt: Activated Akt plays vital roles in cell processes such as survival, 
proliferation, motility, resistance to chemotherapeutic agents, cell cycle progression and  
glucose metabolism by phosphorylating various downstream targets(89,90). 
Phosphorylation of Bad by Akt promotes survival by preventing Bad from binding and 
inhibiting anti apoptotic BCL-xL and from altering the mitochondrial membrane 
potential(110,111) Akt has also been shown to increase antiapoptotic BCL-xL through 
activation of NFκB(112) and Bcl2 by increasing CREB binding to the promotor of 
Bcl2(113). The caspase cascade is also a target for Akt activity. Akt has been shown to 
phosphorylate and inhibit the activity of caspase 9(114). Akt phosphorylation of FKHRL1, 
a forkead transcription factor allows binding to 14-3-3 proteins and subsequent retention in 
the cytoplasm(115-117). This prevents expression of its transcription targets like Fas 
ligand, Bim and IGFBP1 that in turn promote apoptosis(89,118-120). Phosphorylation and 
in-activation of IκB kinase α( IKKα) promotes the activation of both the canonical and non 
canonical  NFκB pathways which play a critical role in cell survival, motility and 
immunity(121-123).  Akt promotes cell cycle progression by regulating cyclin D function. 
This is accomplished by phosphorylation of p27Kip1 and p21Waf1 by Akt(124,125). This 
prevents them from interacting with the respective cyclins. MDM2 has also been shown to 
be a substrate of Akt phosphorylation. Phosphorylation of MDM2 by Akt has been shown 
to be required for the nuclear entry of MDM2 into the nucleus and the steps leading to its 
binding to and degradation of p53(67,85,86). One of the earliest substrates of Akt was 
shown to be Glycogen synthase kinase 3 ( GSK3).GSK-3 is known for phosphorylating 
and thus inactivating glycogen synthase,  proving a role for Akt in the insulin signaling 
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pathway and metabolism(126-128). Akt also plays a role in protein synthesis by increasing 
the phosphorylation of mamalian Target of Rapamycin (mTOR) through the 
phosphorylation of Tuberous Sclerosis Complex (TSC) upstream of mTOR.(129). This 
promotes the activation of p70 ribosomal protein S6 kinase (p70S6K1) and inhibition of 
eukaryotic intiation factor 4E-binding protein1 ( 4EBP1), thus promoting  protein 
synthesis(129-132).  
 
 
 
 
 
 
 
Figure3. Functions of Akt: Activation of Akt promotes phosphorylation and loss of function 
of pro apoptotic proteins including BAD and Caspase9 and increase in anti apoptotic proteins 
like Bcl-2, Bcl-xL..  Akt also phosphorylated MDM2 which reduces p53 levels and therefore 
apoptosis. Akt inhibits cell cycle arrest by phosphorylation of  cdk inhibitors p27and p21 and 
by increasing the activity of the NFκB pathway after phosphorylation of IKKα. By 
phosphorylation of GSK3 Akt prevents phosphorylation of targets like Glycogen synthase, 
thus playing a role in the insulin pathway. Protein synthesis is enhanced by Akt by 
phosphorylation of mTOR and pathway members, p70S6K and 4EBP1. 
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I. Chapter 2. Hypothesis  
a. Major Hypothesis. 
The goal of cancer biology is the identification of biomarkers which can predict the disease 
or the therapeutic response. Cancer is a result of mutation of more than one gene and hence 
deregulation of more than one pathway. It is therefore not possible to attribute the distinct 
cancer phenotypes to mutation in one specific biomarker or another.  MDM2 is amplified 
in many different cancer subtypes. However its value as a prognostic marker remains 
unclear, depending on tumor type, tissue of origin and other factors. It presents a paradox; 
over-expression of MDM2 correlates with poor prognosis in some tumors and good 
prognosis in others. Also over-expression of MDM2 has been shown to offer resistance to 
various chemotherapeutic agents. Only a more profound understanding of the biology 
underlying MDM2 expression and consequence of its expression in different cancer 
subtypes can address the drawback of most translational studies where a reductionist 
approach of tailoring treatment based on the expression of MDM2 alone is followed. 
Therefore the crux of the study is to identify what markers get expressed or repressed as a 
result of MDM2 expression in different cancer subtypes and thus tailor treatment strategies 
for different cancer subtypes.  
The major hypothesis of this work involves deciphering whether p53 independent over-
expression of MDM2 leads to activation of Akt, thus identifying a novel pathway. More 
importantly the study focused if preventing the activation of Akt by MDM2 could render 
drug sensitivity to MDM2 over-expressing cells. This hypothesis was based on previous 
observations in our laboratory and by others. Our laboratory identified that MDM2 
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interacts with the Eukaryotic Translational Elongation Factor EF1α. EF1α was shown by 
various groups to activate the Phosphatidylinositol 4 kinase, which in turn activated the 
Phosphatidylinositol 3 Kinase pathway resulting in activated Protein Kinase B or Akt. This 
was shown to increase actin remodeling and results in increased motility. Therefore the 
fact that MDM2 and EF1α interact led us to ask whether the interaction could lead to the 
Akt activation.  
Further, other groups showed the interaction of MDM2 and Akt in the cytoplasm, and this 
interaction being required by MDM2 for entry into the nucleus. This observation prompted 
us to raise the question on what would happen if there was an enhanced level of MDM2. 
Since MDM2 over-expression has been shown to increase the tumorigenicity of cells, 
mainly by entering the nucleus and degrading p53 and MDM2 required phosphorylated 
Akt to allow its nuclear entry, it should seem implicit that for the higher level of MDM2, 
there should be higher levels of activated Akt. This also fell in place with our observation 
that MDM2 interacted with EF1α and that EF1α was shown to activate the Akt pathway. 
Since the interaction of MDM2 and EF1α was a p53 independent interaction, we asked 
whether MDM2 could activate the Akt pathway independent of p53.  
Since the Akt pathway activation has been correlated to resistance to various 
chemotherapeutic agents; we propose that MDM2 over-expression in cells could render 
resistance to chemotherapeutic agents by activating the Akt pathway. Therefore in subsets 
of tumors where both MDM2 and phosphorylated Akt are co-expressed, agents targeting 
the Akt pathway and thus negating the resistance offered by MDM2 could be plausible 
treatment strategy to investigate. 
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b. Specific Aims. 
The following are the specific aims: 
  1. A. To investigate if MDM2 can induce Akt phosphorylation in a p53 independent   
manner. 
   B. To examine whether MDM2 induced Akt phosphorylation can render the cells 
resistant to Etoposide treatment. 
   2. To decipher the mechanism by which MDM2 can activate the Akt pathway 
   3.  To determine the events downstream of MDM2 mediated Akt phosphorylation 
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J. Chapter 3 
Human Oncoprotein MDM2 enhances Akt phosphorylation at Serine 473 residue, 
reducing sensitivity of cancer cells to chemotherapeutic drugs. 
The manuscript for the work presented in this chapter is currently under preparation. Quantitative RT PCR 
on WI38 cells was performed by Lathika Mohanraj. 
 
a. Introduction. 
MDM2 has been shown to be oncogenic in a p53 independent environment(54,71). Our 
laboratory showed that MDM2 can interact with EF1α(82). Since EF1α is known to up 
regulate PI4Kinase(83) and thereby activate the Akt pathway(84), we wanted to test if 
MDM2 over-expression could result in Akt activation. Also it has been shown by other 
laboratories that MDM2 requires phosphorylation by Akt for its nuclear entry, a 
mechanism by which MDM2 interacts with p53 and degrades it(67,85,86). This has been 
one of the classical mechanisms by which MDM2 induces tumorigenesis. Therefore it 
would be implied that in the presence of more MDM2, Akt phosphorylation would be 
enhanced to facilitate MDM2’s nuclear entry.  
MDM2 has been suggested as an important target for cancer therapy(133). Various 
groups have shown the use of polypeptides(134,135), antibodies(136), small molecule 
inhibitors(137) and antisense approach against MDM2(138-140) as treatment strategies. 
However these studies have raised more questions than answers. Over-expression of 
MDM2 has been shown to offer resistance to various chemotherapeutic agents in some 
cases and in others, sensitization to drugs(141,142). For example, one group evaluated 
the response of 107 patients undergoing surgical resection and adjuvant chemotherapy 
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for esophageal squamous cell carcinoma and found that MDM2 expression correlated 
with shorter survival for patients undergoing post operative chemo- or radiotherapy. In 
stark contrast, a study on advanced breast cancer found that high levels of MDM2 
corresponded to a better response to treatment and longer time to progression. To make 
matters more complicated, other studies have indicated no correlation between MDM2 
expression and response to chemotherapy(141). As of 2005, there were no anti-MDM2 
drugs in clinical trials and only agents blocking expression of relevant molecules were 
being tested(141).  
Numerous groups have reported that the administration of chemotherapeutic agents 
results in the modulation of the PI3K/Akt pathway (143-150). Significantly, the pathway 
has been shown to be activated in response to treatment by chemotherapeutic agents, 
which fall under the category of anthracyclins(143,144), topoisomerase inhibitors(147), 
microtubule agents(149) and DNA damaging agents(148). The activation of the 
PI3K/Akt pathway by these agents has also been shown to correlate with drug 
resistance(143,144,147-149). Since we hypothesize that MDM2 enhances Akt 
phosphorylation, this could be a mechanism of MDM2 mediated drug resistance.  
b. Experimental Results. 
MDM2 induces AKT phosphorylation at Serine 473.  To check if MDM2 expression 
results in the induction of Akt phosphorylation, we chose to transfect non small cell lung 
cancer H1299 (p53-null) or normal diploid WI38 (p53 WT) cells.  The cells were chosen 
to take into account the requirement of p53 and also to find out if this phenomenon could 
be seen in normal cells. To transiently over express MDM2, we nucleofected the cells 
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with MDM2 expression plasmids using a nucleofector and reagents (Amaxa), according 
to the supplier’s protocol. Cell extracts were subjected to Western blot analysis to 
determine the levels of phosphorylated Akt, Akt and MDM2. Western blot analysis using 
an antibody against Akt phosphorylated at Ser 473 indicated that extracts prepared from 
H1299 or WI38 cells transfected with the MDM2 expression plasmid contain 
significantly higher levels of phosphorylated Akt than extracts prepared from vector 
transfected cells (Figure 4A, 4B).  These data show that over-expression of MDM2 
enhances Akt phosphorylation in normal diploid or transformed cells in the presence or 
absence of p53, and therefore Akt phosphorylating function of MDM2 is p53-
independent. 
We tested whether stable over-expression of MDM2 in H1299 cells elevates the levels 
of phosphorylated Akt. For generating H1299 stable transfectants, H1299 cells 
nucleofected with a vector or a MDM2 expression plasmid harboring a neomycin 
resistance gene were selected for neomycin resistant colonies. Pooled colonies were 
maintained in neomycin containing media.  Cell protein extracts were subjected to 
Western blot analysis to determine the levels of phosphorylated Akt, Akt and MDM2.  
The results (Figure 4C) show that stable expression of MDM2 induces phosphorylation 
of Akt in H1299 cells.  
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Silencing of MDM2 expression reduces endogenous Akt phosphorylation at serine 
473: We next determined whether endogenous MDM2 has a role in enhancing Akt 
phosphorylation. An osteosarcoma cell line, SJSA-1, which harbors WTp53 and over 
expresses MDM2(151) was transfected with a short interfering (si) RNA against MDM2.  
Furthermore, three plasmids harboring a puromycin resistance gene were constructed two 
of which expressed two different shRNA against MDM2 and one expressed shRNA 
against a non-specific luciferase gene. The plasmids were nucleofected in SJSA-1 cells.  
Puromycin resistant colonies were generated and pooled.  Extracts prepared from siRNA-
transfected cells or puromycin resistant pooled cell colonies were subjected to Western blot 
analysis to determine levels of MDM2 and phosphorylated Akt.  The results show that 
transfection with MDM2 siRNA diminished MDM2 expression remarkably with a 
Figure 4. MDM2 Induced Akt Phosphorylation at serine 473: Western blot analysis 
of extracts prepared from H1299 (A, C) or WI38 (B) cells transiently (A, B) or stably (C) 
nucleofected with MDM2 expression plasmids (pCMV MDM2, pCMV neo MDM2) or 
vector plasmids (pCMV, pCMV neo). p-Akt was identified with an antibody specific for 
Akt phosphorylated at Ser 473 (#9271 rabbit polyclonal, Cell Signaling); Akt (sc8312 
rabbit polyclonal, Santa Cruz), MDM2 (AB1, Oncogene Science) and actin antibodies 
(AC-15, Sigma) were used to identify Akt, MDM2 and actin. Migration of the control 
MDM2, p-Akt and Akt bands are shown by arrows. 
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corresponding decrease in the levels of phosphorylated Akt compared to control siRNA 
transfected SJSA-1 cells (Figure5A).  Similarly, MDM2 shRNA expressing plasmids 
inhibited MDM2 expression and Akt phosphorylation compared to plasmid expressing 
luciferase shRNA (Figure 5B). These data show that diminished MDM2 expression causes 
reduction in Akt phosphorylation, indicating that endogenously overexpressed MDM2 in 
SJSA-1 cells enhances Akt phosphorylation.  
 
 
 
 
MDM2 induces drug resistance in cancer cells: Various groups have reported the 
modulation of the PI3K/Akt pathway in response to administration of chemotherapeutic 
agents. The pathway has been shown to be activated in response to treatment by 
chemotherapeutic agents, which are used in clinical setting. The activation of the PI3K/Akt 
pathway by these agents has also been shown to correlate with drug resistance(143-150). 
Figure5. Silencing of endogenous MDM2 expression in SJSA-1 cells reduces 
Akt phosphorylation: Western blot analysis of extracts prepared from SJSA-1 
cells (A) transiently transfected with MDM2 siRNA  or non specific scrambled 
RNA and (B) stably transfected with plasmids expressing MDM2 shRNA  
(shMDM2-1, 2 or 3) or luciferase shRNA (shLuc). Migration of MDM2, p-Akt 
CDK4 and actin are indicated. 
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Since MDM2 over-expression led to activation of Akt in our experiments, we decided to 
determine whether the over-expression of MDM2 led to resistance to the chemotherapeutic 
agents, which have been shown to have a decreased efficiency when the Akt pathway is 
activated(143,144,147-149). We chose one example from three classes of 
chemotherapeutic agents: 
Topoisomerase inhibitors: Etoposide, which has been shown to inhibit topoisomerase II.  
Etoposide blocks the ligation step of the DNA replication, generating single and double 
stranded breaks that harm the integrity of the genome. Introduction of these breaks 
subsequently leads to apoptosis and cell death(152). 
Microtubule poison: Paclitaxel; works by interfering with normal microtubule breakdown 
during cell division. Paclitaxel has been shown to a potent mitotic inhibitor(153).  
DNA alkylating agents: Carboplatin; which crosslinks DNA in several different ways, 
interfering with cell division by mitosis. The damaged DNA elicits DNA repair 
mechanisms, which in turn activate apoptosis when repair proves impossible(154). 
To test for drug resistance, we used equal numbers of the control vector and MDM2 over-
expressing H1299 cells that we generated as pooled clones and treated them with 
Etoposide, Paclitaxel or Carboplatin (and appropriate vehicles) and the drug response was 
analyzed by colony formation. Drug sensitivity was determined at increasing Etoposide or 
Paclitaxel concentration and 1.5µM concentration of Carboplatin. The concentrations were 
chosen to reflect the serum levels of these drugs, when used in therapy. Our data show that 
p53-null H1299 cells stably over-expressing MDM2 generated 2- to 5- fold higher number 
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of colonies than vector transfected cells after treatment with Etoposide at all concentration 
ranges (Figure 6A).  Similar results were observed with Paclitaxel (Figure 6B) and 
Carboplatin (Figure 6C). These results suggest that MDM2 can enhance tolerance of 
cancer cells to chemotherapeutic agents.  
 
 
 
 
 
 
Figure6. Over-expression of MDM2 reduces sensitivity of H1299 cells to Etoposide, 
Paclitaxel and Carboplatin.  Colony assays were performed using H1299 cells stably 
transfected with vector or MDM2 expression plasmid after treatment with (A) increasing 
concentration of Etoposide, (B) increasing concentration of Paclitaxel or (C) 1.5 µM 
Carboplatin. Percent survival was calculated considering number of colonies generated in the 
vehicle treated plates to be 100%.  The results are shown by (A,B) semi logarithmic curves 
plotting percent survival against increasing drug concentration, or (C) bar graphs to compare 
percent survival of H1299 stable transfectants after treatment with Carboplatin.  Each 
experiment was performed in triplicate.  Error bars representing standard deviations of the 
colony numbers are shown.  
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Silencing of MDM2 expression increases sensitivity of  cancer cells to Etoposide: To 
determine if endogenous MDM2 plays a role in the resistance to chemotherapeutic agents, 
we used  the MDM2-2 short hairpin expressing SJSA-1 cells ( Figure 5B) which were 
stably maintained  pooled clones. The effect of siRNA wears off after about 48 hours. 
Therefore, we used stable shRNA pooled clones of SJSA-1 to find out what happens when 
there is sustained silencing of endogenous MDM2. Equal numbers of SJSA-1 cells stably 
expressing MDM2 shRNA or luciferase shRNA were either treated with 1µM Etoposide or 
increasing concentrations of Paclitaxel (and the appropriate vehicles). Response of these 
cells to Etoposide and Paclitaxel was determined by colony assay.  Our data show that 
SJSA-1 cells stably over-expressing MDM2 shRNA reproducibly generated 2-fold less 
number of colonies than luciferase shRNA expressing cells after treatment with Etoposide 
(Figure 7C) and 2-4 fold less number of colonies than luciferase shRNA expressing cells 
after treatment with increasing concentrations of Paclitaxel, showing that reduction in the 
levels of endogenous MDM2 enhances susceptibility of the cells to Etoposide and 
Paclitaxel.  These data indicate that endogenously over-expressed MDM2 contributes to 
the tolerance of the cancer cells to Etoposide and Paclitaxel. 
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Silencing of MDM2 expression increases sensitivity of normal diploid cells: Antisense 
approach to target MDM2 in cancer cells has been proposed by various groups to be a 
potential therapeutic strategy. The advantage antisense oligos are thought to have over 
other approaches like small molecule inhibitors (for eg: nutlin) is that it can target both 
p53 dependent and independent contribution of MDM2 towards oncogenesis.  Synergistic 
studies using antisense oligos and chemotherapy have been shown to increase therapeutic 
effectiveness. However, not much is known on whether this approach may result in a 
similar cell death in normal cells; not just pertaining to the cancer environment, but also 
elsewhere in the body(142). This has been considered a potential drawback, since MDM2 
Figure7. Silencing of MDM2 expression increases sensitivity of cancer cells to 
chemotherapeutic agents: Colony assays were performed in SJSA-1 cells, stably 
transfected with Sh RNA against MDM2 or Luciferase expression plasmid after treatment 
with (A) 1µM of Etoposide or (B) increasing concentration of Paclitaxel. Percent survival 
was calculated considering number of colonies generated in the vehicle treated plates to be 
100%.  The results are shown by bar graphs (A) or logarithmic curves plotting percent 
survival against increasing drug concentration (B). Percent survival was calculated 
considering number of colonies generated in the vehicle treated plates to be 100%.    Each 
experiment was performed in triplicate. Error bars are shown and represent standard 
deviations of the colony numbers.   
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expression in normal cells is extremely low and the balance is required for prevention of 
p53 activation in normal cells. To determine if endogenous MDM2 silencing in normal 
cells plays a role in the resistance to chemotherapeutic agents, we used MCF-10A, which 
is a non-tumorigenic epithelial cell line which is a surrogate for normal epithelial 
cells(156) and WI38, diploid lung fibroblasts. We used a lentiviral approach to silence 
MDM2 in these cells. In short, the plasmids expressing the short hairpin RNA against 
MDM2 were packaged inside a lentivirus system and used to infect the plated cells. This 
ensured a more efficient delivery of the plasmids into the cells and stable 
incorporation(157,158) (Figure 8B).  Since the plating efficiency of WI38 cells was too 
low for clonogenic assays, following the infection equal numbers of the WI38 cells were 
plated in 6 cm dishes and treated with either Etoposide (1µM), Paclitaxel (25nM) or the 
respective vehicles and the cells were counted on a daily basis to check for the numbers 
using a coulter counter, which reflected the survival rate of the cells (Figure 8A). MCF-
10A cells were infected with the lentivirus packaged with plasmids expressing short 
hairpin RNA targeting either non specific luciferase or MDM2 and equal number of cells 
were plated and treated with Etoposide (1µM), Paclitaxel (25nm) or appropriate vehicle. 
Response of the cells to drug was determined by clonogenic or colony assays.  
WI38 cells treated with shMDM2 were at least 2 times more susceptible to the treatment 
with Etoposide and Paclitaxel by day 7. By day 12, mere silencing of MDM2 in these 
cells, kills them. Also the cells show considerable death in response to drug treatment. 
MCF-10A cells also showed decreased colony formation when treated with the shRNA. 
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These results indicate that silencing MDM2 by antisense approach can lead to non 
targeted effects and potentially kill normal cells. 
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An inhibitor of Akt activation, Akt inhibitor III (SH-6) inhibits MDM2-mediated Akt 
phosphorylation at serine 473 and MDM2-mediated reduction of Etoposide 
resistance: Since our data suggest that MDM2 activates Akt phosphorylation (Figure 4A-
C), and reduces Etoposide sensitivity of cancer cells (Figures 6A, 7A), we determined if an 
inhibitor of Akt phosphorylation would abrogate ability of MDM2 to alter Etoposide 
sensitivity.  For this purpose H1299 stable transfectants (vector and MDM2 expressing 
cells) were pretreated with Akt inhibitor SH-6 or the vehicle (DMSO) for four hours. Sh-6 
is a phosphatidylinositol analog that inhibits the activation of Akt and select downstream 
substrates without decreasing phosphorylation of PDK-1 or other kinases downstream of 
Ras(159,160). Equal numbers of treated cells were then either plated to determine their 
sensitivity to Etoposide by colony development, or harvested to prepare cell extracts to 
determine Akt phosphorylation and MDM2 expression by Western blot analysis.  The 
results of our colony assay show that while the MDM2 over-expressing H1299 stable 
transfectants pre-treated with DMSO generated approximately 3-fold higher number of 
Figure8. Silencing of MDM2 expression increases sensitivity of normal cells to 
chemotherapeutic agents: Growth assay was performed using WI38 cells infected 
with lentivirus packaged with plasmid expressing shRNA against MDM2 or 
nonspecific luciferase using 1µM Etoposide, 25nM Paclitaxel or relevant vehicle. Cell 
numbers on Day 7(A) and Day 12(B) after drug treatment are shown by bar graphs. 
Knockdown of endogenous levels of MDM2 RNA by the shRNA was done in WI38 
cells and checked by quantitative RT PCR. The relative fold levels are shown by bar 
graph (C).The RT PCR was done in technical triplicates. Error bars represent the 
standard deviations. Colony assays were performed using (D) MCF-10A cells infected 
with lentivirus packaged with non specific luciferase shRNA or shRNA against 
MDM2 using 1µM of Etoposide, 25nM of Paclitaxel or relevant vehicles. Percent 
survival was calculated considering number of colonies generated in the vehicle 
treated plates to be 100%.  The results are shown by bar graphs. Each experiment (A, 
B and D) was performed in triplicate.  Error bars indicate the standard deviations. 
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colonies than the corresponding vector-transfected stable transfectants after exposure to 
Etoposide, pre-treatment with SH-6 abrogated the ability of MDM2 to enhance the 
tolerance of H1299 stable transfectants to this drug (Figure 9A).  The Akt inhibitor SH-6 
inhibited Akt phosphorylation in both the stable transfectants as expected (Figure 9B).  
This data shows that MDM2-mediated Akt phosphorylation is required for its ability to 
enhance Etoposide tolerance of H1299 cells. 
 
 
 
 
 
 
Increased Akt activation by MDM2 leads to enhanced proliferation rate: The Akt 
pathway activation has been shown to increase the proliferation of cells towards 
Figure9. Inhibition of Akt phosphorylation inhibits the ability of MDM2 to decrease 
Etoposide sensitivity.  Left panel (A) shows a bar graph to compare number of colonies 
generated after treatment of H1299 stable transfectants (vector and MDM2 expressing) with 
1.76 μM SH-6 or DMSO followed by 6μM Etoposide and colony formation assay. The 
normalized number of colonies represents the ratio of colony numbers generated after 
treatment of cells with Etoposide to the number of colonies treated with vehicle. 
Experiments were done in triplicates and error bars indicating the standard deviations of the 
number of colonies formed are shown. The right panel (B) shows inhibition of MDM2-
mediated Akt phosphorylation by SH-6.  Akt and MDM2 expression are also indicated. 
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oncogenesis(87-89). Therefore we did a proliferation assay to find out if MDM2 over-
expressing cells had increased proliferation rates. Also we tested whether inhibiting the 
Akt pathway could render reduce the proliferation rate. H1299 stable transfectants (vector 
and MDM2 expressing cells) were pretreated with Akt inhibitor SH-6 or the vehicle 
(DMSO) for four hours. Equal numbers of treated and untreated cells were plated and 
allowed to grow. They were harvested and counted each day after plating and the growth 
rates plotted. Our results show that while MDM2 over-expressing cells had enhanced 
proliferation rate, it dropped to the rate of the control cells when the Akt phosphorylation 
in the cells was limited (Figure 10) 
 
 
 
 
 
Figure10. Increased Akt activation by MDM2 leads to enhanced proliferation rate. 
H1299 stable transfectants (vector and MDM2 expressing) were pretreated with 1.76 
μM SH-6 or DMSO and plated.  The cells were harvested each day and the numbers 
were counted using a coulter counter. They were normalized to the counts on day 1, 
which was used for plating efficiency. The experiments were done as technical triplicate 
and error bars representing the standard deviations of the counted cell numbers are 
shown. 
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Inhibition of Akt phosphorylation by SH-6 is not cytotoxic to normal cells:  Next, we 
determined cytotoxicity of SH-6; whether pretreatment of SH-6 led to reduced number of 
colonies after plating. For this purpose WI38 were pretreated with Akt inhibitor SH-6 or 
the vehicle (DMSO) for four hours. Equal number of treated cells were either plated to 
determine their ability to form colonies, or harvested to prepare cell extracts to determine 
Akt phosphorylation by Western blot analysis.  The results of our colony assay show that 
SH-6 treated cells did not have decreased colony formation ability when compared to the 
cells pretreated with the vehicle. (Figure 11A).The Akt inhibitor SH-6 inhibited Akt 
phosphorylation in WI38 as expected (Figure 11B).  This data shows that using SH-6 at the 
concentration of 1.76µM is not cytotoxic to normal diploid cells. 
 
 
 
 
 
Figure11. Inhibition of Akt phosphorylation by SH-6 does not result in cell death.  Left 
panel (A) shows a bar graph to compare number of colonies generated after treatment of 
WI38 with 1.76 μM SH-6 or DMSO.  The plating was done in triplicates and the error bars 
indicate the standard deviation of the number of colonies generated. The right panel (B) 
shows inhibition of Akt phosphorylation by SH-6.  Total Akt is used as loading control and 
indicated. 
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c. Chapter Summary. 
The human oncoprotein MDM2 interacts with the protein kinase B/ Akt that 
phosphorylates MDM2. Our observation shows that MDM2 enhances Akt 
phosphorylation at Ser 473. Stable over-expression of MDM2 expression reduces 
sensitivity of cells to chemotherapeutic drugs such as Etoposide, Carboplatin or 
Paclitaxel. MDM2 over-expression also leads to increased proliferation rate. Silencing 
of endogenous MDM2 expression inhibits Akt phosphorylation and enhances their 
sensitivity to Etoposide and Paclitaxel suggesting endogenous MDM2 participates in 
Akt phosphorylation and alteration of sensitivity to chemotherapeutic agents. An 
inhibitor of Akt phosphorylation abrogated MDM2-mediated Akt phosphorylation and 
reduced Etoposide sensitivity indicating that MDM2 reduces sensitivity of cancer cells 
by activating the Akt phosphorylation. Also inhibition of Akt phosphorylation resulted 
in decreased proliferation rate in MDM2 over-expressing cells. Our observation reveals 
a novel signaling function of MDM2, important for enhanced survival and proliferation, 
both characteristics of cancer cells. 
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K. Chapter 4. 
Mechanism of MDM2 mediated activation of Protein Kinase B/Akt. 
The manuscript for the work presented in this chapter is currently under preparation. The q-RT PCR for 
CXCL8 transcripts and migration assay was performed by Dr Andrew Yeudall. 
a. Introduction. 
 In order to decipher a mechanism by which MDM2 expression resulted in activation of 
Akt, we decided to investigate the players involved in the PI3K/Akt pathway and what 
modulations were observed because of MDM2 over-expression. Akt is activated in 
response to a wide range of stimuli. These include growth factors, serum, survival factors 
and agonists which act through surface receptors. Besides these, Akt has been shown to be 
activated in response to various cellular insults such as oxidative and osmotic stress, 
irradiation and treatment of cells with chemotherapeutic agents and ischemic 
shock(89,90,93-95,104,161). Inhibition of cellular phosphatases also has been shown to 
activate Akt(161,162). It has been shown that the phosphorylation event in Akt follows it’s 
docking to the plasma membrane and this requires the activation of the PI3K 
pathway(100,101,163,164). Though recent reports have shown PI3K independent 
mechanism of Akt activation(99), it still serves as the most well studied mechanism of Akt 
activation. Akt activation is a two step process; phosphorylation of Akt at Threonine 308 is 
followed by Serine 473 phosphorylation for full activation of the kinase. PDK1 is a well 
known kinase responsible for the phosphorylation of Akt at threonine 308(161). Though 
kinases such as Rictor(99), DNA-PK(104), ILK(100-102)  have been shown to 
phosphorylate Akt at serine 473, it is thought that phosphorylation of Akt at this residue 
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can be effected by other kinases present in the cell, depending on the conditions under 
which Akt is activated. Regulation of Akt is further dependent on the levels and activity of 
phosphatases like PTEN(105,165), SHIP(98), PHLPP(106,107), PP2A (108)and proteins 
like CTMP(110).  
MDM2 has no known kinase activity, though it has a defined ATP binding site. Most of its 
tumorigenic properties are attributed to the interaction of MDM2 with other proteins. The 
domains of MDM2 with which the different protein interact have been mapped out by 
previous studies.(54,166) Therefore information on what proteins could interact could be 
had using deletion mutants. This approach could give a broad idea on what mechanism 
may be employed by MDM2 in the activation of the Akt pathway. 
b. Experimental Results: 
A PI-3 kinase inhibitor Wortmannin inhibits MDM2-mediated Akt phosphorylation. 
To determine if MDM2 requires the PI-3 kinase pathway to activate Akt 
phosphorylation, MDM2-mediated Akt phosphorylation was analyzed in the presence of 
Wortmannin, which can inhibit PI-3 kinase activity(167,168). H1299 cells stably 
expressing MDM2, or stably transfected with vector plasmid were treated with 
Wortmannin for 4 hours. Extracts from Wortmannin or vehicle (DMSO) treated cells 
were subjected to Western blot analysis as described earlier. The results of this analysis 
show that Wortmannin inhibits Akt phosphorylation as expected, and cells stably 
expressing MDM2 cannot activate Akt phosphorylation after treatment with 
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Wortmannin (Figure12B).  This observation suggests that MDM2 up regulates PI3-
kinase mediated Akt Phosphorylation. 
 
 
 
 
 
MDM2 enhances IGF-1mediated phosphorylation of Akt: IGF-1 has been shown by 
various groups to mediate Akt phosphorylation through the PI3K pathway(169-172). To 
further validate the role of the PI3K pathway in the activation of Akt due to MDM2 over-
expression, we treated H1299 cells with IGF-1 for 10 minutes after nucleofecting with the 
MDM2 expressing plasmid. These cells were serum starved for 5 hours prior to the 
addition of the IGF-1. Our results (13A) showed that there was enhanced Akt 
phosphorylation in the presence of MDM2 when IGF-1 was added. Next, we silenced 
MDM2 in SJSA-1 cells and tested the response of the cells to IGF-1 treatment. We 
observed that silencing MDM2 reduced the phosphorylation of Akt by IGF-1 treatment 
Figure12. MDM2 enhances Akt phosphorylation at Ser 473 through PI3-kinase 
pathway.  Treatment of H1299 stable transfectants with Wortmannin, an inhibitor 
of PI3-kinase, inhibits MDM2-mediated Akt phosphorylation.  p-Akt was identified 
with an antibody specific for Akt phosphorylated at Ser 473 (#9271 rabbit 
polyclonal, Cell Signaling); Akt (sc8312 rabbit polyclonal, Santa Cruz), MDM2 
(AB1, Oncogene Science) and actin antibodies (AC-15, Sigma) were used to 
identify Akt, MDM2 and actin. Migration of the control MDM2, p-Akt and Akt 
bands are shown by arrows. The link between PI3-kinase and Akt phosphorylation 
is shown in a cartoon (A) 
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(13B). Together, these results indicate that MDM2 enhances the IGF-1 signaling. Since 
IGF-1 signaling works through the PI3K pathway it would seem that MDM2 serves to 
activate one or more components of the PI3K pathway. 
 
 
 
 
 
 
 
MDM2 does not influence phosphorylation of Akt at Threonine 308 residue: Akt 
activation requires the phosphorylation of Akt at threonine 308 and serine 473 residues. 
There is still a debate on whether threonine 308 phosphorylation follows phosphorylation 
Figure13. MDM2 enhances IGF-1mediated phosphorylation of Akt. (A) Cell 
extracts of H1299 cells, serum starved 3 hours post nucleofection withMDM2 
expression plasmids or empty plasmid and and treated with 50ng/ml IGF-1 for 10 
minutes were analyzed by western blotting, 8 hours post nucleofection. Cell extracts of 
SJSA-1 cells (B) infected using lentivirus packaged with plasmids expressing shRNA 
against MDM2or non specific Luciferase for 4 days and treated with 50ng/ml IGF-1 for 
10 minutes were analyzed by western blotting.  p-Akt was identified with an antibody 
specific for Akt phosphorylated at Ser 473 (#9271 rabbit polyclonal, Cell Signaling); 
Akt (sc8312 rabbit polyclonal, Santa Cruz), MDM2 (AB1, Oncogene Science), 
GAPDH(sc32233,SantaCruz) and CDK4 (AB2,Oncogene Science)  were used to identify 
Akt, MDM2,GAPDH and CDK4. Migration of the control MDM2, p-Akt and Akt 
bands are shown by arrows.  
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of Akt at serine 473 or occurs before it(99,164,173) Akt phosphorylation at threonine 308 
residue is shown to require the PI3K pathway and the kinase PDK1.(100,101,163,164,173) 
Since MDM2 requires the PI3K pathway for the activation of Akt at serine 473 residue, we 
checked whether MDM2 over-expression leads to increase in Threonine 308 
phosphorylation of Akt. This would also indicate that both events happen when Akt is 
docked to the membrane and that the increased Akt phosphorylation happens by the 
induction of some upstream signaling pathway by MDM2. Our data shows that there is no 
increase in phosphorylation of Akt at threonine 308 due to the over-expression of MDM2 
(Figure 14B). This could mean that either MDM2 mediates phosphorylation of Akt 
specifically at serine 473 or that the threonine 308 activation pathway in H1299 is 
deregulated. 
 
 
 
 
 
Figure14. MDM2 does not influence phosphorylation of Akt at threonine 308 
residue.  Cell extracts of H1299 stable transfectants were analyzed by western blotting. 
p-Akt was identified with an antibody specific for Akt phosphorylated at Threonine 308 
(#9275rabbit polyclonal, Cell Signaling) and actin antibodies (AC-15, Sigma) was used 
to actin. Migration of the p-Akt and actin bands are shown by arrows.  The cartoon (A) 
shows the 2 phosphorylation residues of Akt required for its full activation. 
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MDM2 does not influence the cross talk of ERK pathway and Akt: Similar to the Akt 
activation of MDM2, the Ras –Raf- MEK-ERK pathway has also been shown to lead to 
phosphorylation of MDM2 and subsequent degradation of p53(174). Also there exists a 
crosstalk between the Ras –Raf- MEK-ERK and the PI3K-Akt pathway on the level of 
Raf-1 and Akt. Depending on the cell type and conditions, the two pathways have been 
shown to either act synergistically for survival or antagonistically with the Erk activation 
leading to growth arrest and Akt pathway leading to proliferation(175).Therefore we 
determined if there existed any correlation with MDM2 expression and the activation of 
the Ras-Raf- MEK-ERK pathway. If such a correlation existed, it could serve as a lead for 
a possible mechanism of activation of the Akt pathway.  We checked initially if over-
expression of MDM2 could modulate the phosphorylated MAP kinases (ERK1 and 
ERK2). We chose both diploid fibroblast where we over-expressed MDM2 and the MDM2 
over-expressing stable H1299 cells and determined the levels of p-ERK1/2.  Our results 
(Figure 15) show that MDM2 does not activate or lower the p-ERK1/2 levels. Therefore 
our observation was specific to the PI3K- Akt pathway. 
 
 
 
Figure15. MDM2 does not influence the cross talk of ERK pathway and Akt.  
Cell extracts of H1299 stable transfectants and WI38 trasfected with 4µg of MDM2 
or corresponding vector expressing plasmid, were analyzed by western blotting. p-
ERK1/2 was identified with an antibody specific for pERK(V-8031) from Promega  
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Silencing Rictor does not inhibit the ability of MDM2 to activate Akt at serine 473. 
The mammalian target of Rapamycin/ Rapamycin Insensitive Companion of mTOR 
(mTOR/Rictor) complex is a kinase known to be able to phosphorylate Akt at 
serine473(99).  Since we did not observe any change in the levels of threonine 308 
phosphorylation of Akt when MDM2 was over-expressed, we determined whether this 
serine 473 specific kinase complex played a role in our observation. For this purpose, we 
made lenti virus packaged with a plasmid expressing Rictor shRNA and infected the 
H1299 cells for 4 days, and then nucleofected with MDM2 expressing plasmid or control 
empty vector. Our results show that silencing Rictor in the MDM2 over-expressing H1299 
cells did not reduce the levels of Akt phosphorylated at serine 473 and that it was enhanced 
in comparison with the H1299 transfected with a plasmid expressing just the vector (Figure 
16A). This verified that MDM2 does not require the mTOR/ Rictor complex to induce 
phosphorylation of Akt at serine 473 residue. Taken together with the fact that the PI3K 
pathway is required for the activation, it would seem to suggest that the pathway leading to 
the phosphorylation of threonine 308 residue is deregulated. 
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MDM2 over-expressing cells do not show decreased levels of PHLPP and CTMP 
transcripts. Regulation of the PI3K/Akt pathway is also controlled by cellular 
phosphatases. Since H1299  has suppressed PTEN expression due to  promotor 
methylation and our observation was specific to the serine 473 residue, we decided to look 
at the the pH domain and leucine rich repeat protein phosphatase (PHLPP), which was 
specific for dephosphorylation of the serine 473 residue(106,107).  We also looked at the 
Carboxy Terminal Modulating Protein (CTMP) which binds to Akt and dephosphorylates 
it(109).  We checked for the transcript levels of the phosphatases in the cell to find out if 
MDM2 over-expression led to their reduced levels.  Our data shows that there is no 
significant change in the transcript levels of both PHLPP (Figure 17A) and CTMP 
(Figure17b) in the presence of MDM2. 
 
Figure16. Silencing Rictor does not inhibit the ability of MDM2 to activate Akt at 
serine 473.  Cell extracts of H1299 infected using lentivirus packaged with plasmids 
expressing shRNA against Rictor or non specific luciferase for four days and then 
nucleofected with either empty vector or vector expressing MDM2 were prepared and 
analyzed by western blotting. p-Akt was identified with an antibody specific for Akt 
phosphorylated at Ser 473 (#9271, Cell Signaling); Akt (sc8312 rabbit polyclonal, Santa 
Cruz), MDM2 (AB1, Oncogene Science) and Rictor (#2114,Cell signaling), antibodies  
were used to identify Akt, MDM2 and Rictor. Migration of the control MDM2, Rictor, 
p-Akt and Akt bands are shown by arrows. The link between Rictor and Akt 
phosphorylation is shown in a cartoon (B)
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MDM2 over-expressing cells show enhanced CXCL8 transcript levels and faster 
migration rate: Interleukin 8(IL8, CXCL8) is a cytokine that has been shown to 
increase cell proliferation in non small lung cancer cells similar to our observation with 
MDM2 over-expression(176) (Figure 10). Interestingly, IL8 has been shown to activate 
the Akt pathway through the PI3K pathway, after phosphorylation of Cbl.(177) 
Therefore we checked the levels of CXCL8 in our MDM2 over-expressing stable H1299 
cell lines. Our results show that MDM2 over-expressing stable cells expressed enhanced 
transcript levels of IL-8 (Figure18A). Since IL-8 has been implicated in promotion of 
migration(178), we did a migration/scratch assay in our cells and found that MDM2 
over-expressing cells migrate faster than control cells (Figure18B). Therefore by 
Figure17. MDM2 over-expressing cells do not show decrease levels of PHLPP and 
CTMP transcript levels. Normalized fold change in transcript levels determined by qPCR 
are shown by bar graphs.  An endogenous GAPDH control was used to ensure equal mRNA 
levels in each sample.  The normalized transcript levels of (A) PHLPP and (B) CTMP are 
shown. Experiments were done as technical triplicates and error bars indicating the standard 
deviations is shown (C) Cartoon depicting the dephosphorylation events of Akt by CTMP 
and PHLPP. 
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increasing CXCL8 levels, MDM2 could activate the Akt pathway and this could be a 
mechanism by which we see increased activation of Akt in the presence of MDM2.  
 
 
 
 
 
 
 
The p53 interaction domain of MDM2 is dispensable for Akt phosphorylation. 
Since MDM2 is a multifunctional protein, and many of its functional domains have 
been identified, we determined the domain of MDM2 responsible for activating Akt 
phosphorylation.  For this purpose MDM2 or its C- or N-terminal deletion mutants were 
transiently over-expressed in H1299 cells as described earlier(179). To determine the 
consequence of stable expression, H1299 cell lines stably expressing C- and N-terminal 
deletion mutants of MDM2 were also generated. Extracts prepared from these cells were 
subjected to Western blot analysis to detect Akt phosphorylation and expression of 
Figure18. MDM2 over-expressing H1299 cells show enhanced CXCL8 transcript 
levels and faster migration rate. (A) Normalized fold change in transcript levels of 
CXCL8 determined by qPCR is shown by bar graphs.  An endogenous Actin control was 
used to ensure equal mRNA levels in each sample. Triplicates of the samples were 
analyzed and error bars representing standard deviations are shown. (B) Migration assay 
was performed on H1299 stable transfectants by scratching the plate with a pipette tip and 
allowing the cells to grow. The scratch closure was analyzed after 24 hours. 
 51 
 
MDM2 deletion mutants.  Our data (Figure 19 B,C) show that an N-terminal deletion 
mutant of MDM2 (Del 1-120) lacking 120 amino acid residues is capable of activating 
Akt phosphorylation, whereas a C-terminal deletion mutant of MDM2 (Del 491-155) 
harboring N-terminal 154 amino acids is inactive in Akt phosphorylation.  Thus the Akt 
phosphorylating activity of MDM2 is located within 121 to 491 amino acid residues 
which is C terminal to the p53 binding domain although the sequences at the N-terminal 
of MDM2 may be necessary for optimal activity.   
 
 
 
 
 
 
Figure19. The p53 interaction domain of MDM2 is dispensable for Akt 
phosphorylation.  The known functional domains of MDM2 are indicated (A). Akt 
phosphorylating ability of the full-length and deletion mutants of MDM2 was determined by 
Western blot analysis after their transient (B) and stable (C) expression in H1299 cells. A 
mouse monoclonal antibody 2A10 was used to detect the N-terminal deletion mutant of 
MDM2 (Del 1-120), and a rabbit polyclonal antibody N20 was used to detect the C-terminal 
deletion mutant Del 491-155.  Other antibodies have been described in Figure 4. 
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The Akt phosphorylating domain of MDM2 is responsible for altering Etoposide 
sensitivity. Since our data show that Akt phosphorylating activity of MDM2 is required 
for MDM2-mediated alteration of Etoposide sensitivity (Figure 9), we tested whether N-
terminal 120 amino acid residues of MDM2 is required for this function. For this 
purpose equal number of H1299 stable transfectants expressing full-length MDM2 or its 
deletion mutants (Del 1-120 an Del 491-154) were plated, and their sensitivity to 
Etoposide was determined by colony development. The results (Figure 20) show that 
H1299 cells stably expressing MDM2 generated higher number of colonies than H1299 
cells stably transfected with the vector. The stable transfectants expressing the C-
terminal deletion mutant Del 491-155 did not show this effect, whereas the N-terminal 
deletion mutant Del 1-120 also generated higher number of colonies than vector stable 
transfectants. These data suggest that the Akt phosphorylating activity of MDM2 is co-
located with its ability to enhance Etoposide tolerance of the cancer cells.                                   
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Inhibition of Akt phosphorylation renders the cells expressing deletion mutant Del 1-
120 sensitive to Etoposide treatment.  To show that Del1-120 expressing cells provided 
resistance to Etoposide by augmenting the Akt pathway, we used the Akt inhibitor, SH-6 
to inhibit the Akt phosphorylation and performed clonogenic assays as described earlier 
with Etoposide. Our results clearly shows that Sh-6 inhibits Akt phosphorylation( Figure 
21B) and these cells became sensitive to the treatment with Etoposide (Figure21A). 
 
 
 
 
Figure20. The Akt phosphorylating domain of MDM2 is responsible for altering 
Etoposide sensitivity.  Bar graph to compare number of colonies generated after treatment of 
H1299 stable transfectants expressing full length, either deletion mutants or control vector with 
6µM Etoposide or DMSO. The results shown are representative of 2 different experiments, 
with the vector and full length MDM2 harboring stable cells common to both. Percent survival 
was calculated considering number of colonies generated in the vehicle treated plates to be 
100%.  The experiments differed in the use of the deletion mutant. Experiment was done in 
triplicates and error bars representing standard deviations are shown. 
Figure21. Inhibition of Akt phosphorylation renders the cells expressing deletion 
mutant Del 1-120 sensitive to Etoposide treatment.  Panel (A) shows a bar graph to 
compare number of colonies generated after treatment of H1299 stable transfectants 
expressing deletion mutants with 1.76 μM SH-6 or DMSO and colony formation assay 
with 6µM Etoposide. Panel (B) shows inhibition of Akt phosphorylation by SH-6.  Total 
Akt is used as loading control and indicated. 
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The phosphorylated Akt-MDM2 interaction domain is required for the increased Akt 
phosphorylation in the presence of MDM2. To fine map the domain of MDM2, we 
performed further deletion mutant analysis with deletion mutants 1-189 and deletion 
mutants 491-220(179) H1299 cells were nucleofected with 4µg of plasmids expressing 
either full length, deletion 1-189, deletion 491-220 or control vector, harvested after 8 
hours and analyzed by western blotting. Our results show that both the deletion mutants 
and full length MDM2 enhance the levels of Akt phosphorylation (Figure 22B). Taken 
together with our previous deletion mutant analysis, we inferred that the region between 
amino acids 189-220 was required for our observation. Interestingly, work from other 
laboratories have shown this to be the region that interacts with phosphorylated Akt in 
the cytoplasm which leads to phosphorylation of MDM2 and the consequent entry of 
MDM2 into the nucleus.  
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c. Chapter Summary.                                                                                                                   
To determine the mechanism by which MDM2 activates the Akt pathway, we tested the 
importance of the PI3K signaling pathway and found that it was required for the activation. 
As shown by the addition of IGF-1, there is an augmentation of Akt phosphorylation which 
seems to be an upstream signaling event. However, there is no change in the level of the 
Threonine 308 phosphorylation on Akt. It could very well be that the pathway leading to 
the phosphorylation of Threonine 308 could be deregulated and this requires further 
investigation. To further investigate the point that Akt may require the PI3K pathway for 
its activation in the presence of MDM2, we show that Rictor has no role in this MDM2 
mediated Akt phosphorylation. Also transcript levels of known phosphatases like PHLPP 
and Akt binding protein CTMP which serves to de phosphorylate Akt are not shown to be 
reduced. Since these seem to suggest an extracellular membrane bound receptor mediated 
signaling event, we checked if there is any increase in IL-8 transcript levels and find that it 
is higher in the presence of MDM2. Also supporting the result is the fact that MDM2 over-
expressing cells migrate faster. So this seems to be a plausible mechanism by which 
MDM2 activates Akt; more experiments are needed to confirm it. 
Figure22.  The phosphorylated Akt-MDM2 interaction domain is required for the 
increased Akt phosphorylation in the presence of MDM2.  The known functional 
domains of MDM2 are indicated (A). Akt phosphorylating ability of the full-length and 
deletion mutants of MDM2 were determined by Western blot analysis after their transient 
expression in H1299 cell line (B). A mouse monoclonal antibody 2A10 was used to detect 
the N-terminal deletion mutant of MDM2 (Del 1-89), and a rabbit polyclonal antibody N20 
was used to detect the C-terminal deletion mutant Del 491-220.  Other antibodies have been 
described in Figure 4. 
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Since the domains of MDM2 are well mapped out and their interacting partners have been 
studied over the years, we did a deletion analysis to figure out what domain(s) of MDM2 
was/were responsible for our observation. Interestingly, we found that the region of 
MDM2 implicated by others to be responsible for binding to Akt in the cytoplasm is the 
region, which when present augments Akt phosphorylation in our experiments. This falls 
well into our hypothesis that MDM2 would need Akt phosphorylation for its oncogenic 
properties like increased growth, migration and survival. 
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L. Chapter 5 
Determination of events downstream of MDM2 mediated Akt phosphorylation. 
The manuscript for the work presented in this chapter is currently under preparation.  
a. Introduction. The PI3K/Akt pathway activation has been shown to be involved in 
proliferation, migration, survival, insulin signal transduction and chemotherapeutic 
resistance through the phosphorylation of downstream substrates(89,90) (Figure3). Akt 
activation mediates many of the cellular effects of insulin. Insulin mediated Akt activation 
has been shown to be severely diminished in patients with Type 2 diabetes. The targets in 
this pathway include the Glycogen Synthase Kinase (GSK3)(180,181), Mammalian Target 
of Rapamycin (mTOR) (182,183)and Insulin Receptor Substrate( IRS-1)(184,185) among 
others.  Over-expression of Akt has been shown to have an anti apoptotic effect in many 
cell types.  The components of the apoptotic machinery including the Bcl-2 family 
proteins, caspases and transcriptional regulators of apoptosis like Fas ligands, have been 
shown to be influenced by the Akt activation(89,113,114,118). Akt has been shown to 
increase proliferation and migration by its ability to phosphorylate the IκB kinases ( IKKs) 
and thereby activate the NFκB pathway(121-123). Akt activation has also been shown to  
increase in cyclin D levels(124,125). PKB has also been shown to be involved in inducing 
angiogenesis by activating endothelial Nitric Oxide Synthase (eNOS), resulting in the 
sustained production of Nitric Oxide by endothelial cells(186-188). 
We therefore set out to determine if MDM2 mediated Akt phosphorylation can result in the 
activation of known substrates of Akt and to try and map out the pathways that result in 
MDM2 mediated increased proliferation, migration and chemotherapeutic resistance.  
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b. Experimental results. 
MDM2 over-expressing cells show increased GSK3α/β phosphorylation: A well known 
target of Akt is the kinase GSK3, a component of the Wnt pathway. GSK3α and GSK3β 
have shown to be involved in the phosphorylation and degradation of βcatenin, thus 
inhibiting β catenin’s transcriptional effects. The activity of GSK3 is normally suppressed 
in proliferating cells by phosphorylation mediated by Akt and other kinases(126-128). We 
therefore looked at whether MDM2 over-expression led to the modulation in the levels of 
GSK3 phosphorylation. We observed that while MDM2 expressing cells had enhanced 
levels of phosphorylated GSK3α/β (Figure 23A), treatment of the cells with Sh-6 abrogates 
it (Figure23B). Further, silencing of endogenous MDM2 in SJSA-1 cells lowers the 
phosphorylation of GSK3α/β. Therefore these results seem to suggest that MDM2 
mediated Akt phosphorylation results in the phosphorylation of downstream GSK3α/β. 
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Induction of MDM2 elevates known Akt targets involved in proliferation, migration 
and chemo resistance pathways:  Since MDM2 over-expression led to enhanced Akt 
phosphorylation and increased proliferation, migration and resistance to chemotherapeutic 
agents, we decided to do a RT profiler PCR array (SuperArray) to get a broad idea of 
which genes are differentially regulated by MDM2 over-expression(189,190). Since the 
functions of most of the genes in the PI3K/Akt pathway have been well characterized, this 
would give us an insight on the various pathways that were getting activated because of 
MDM2 mediated Akt phosphorylation. We developed a Ponasterone inducible clone that 
expressed MDM2 when Ponasterone was added to the media (Figure24A)(191,192). We 
isolated the RNA, made cDNA and used it in our array consisting of 84 genes. The genes 
that showed the most significant changes are shown (Figure 24C). Genes like Fibronectin 
and PECAM-1 play a major role in cell adhesion, growth, migration and differentiation, 
and are important for processes such as wound healing and embryonic development. These 
have been shown to be able to activate the Akt pathway(193). Further study will confirm if 
they are involved in the mechanism by which MDM2 enhances Akt phosphorylation. The 
Activator Protein1/cJun transcription factor has been implicated in various cancers and has 
been shown to be activated by the Akt pathway(194). IL8 expression was enhanced just as 
Figure23. MDM2 over-expressing cells show increased GSK3α/β phosphorylation: 
(A) H1299 stable transfectants expressing MDM2 or empty vector were pretreated with 
1.76µM SH-6 or DMSO for 4 hours, harvested and analyzed by western blotting.(B) 
Densitometric analysis  on (A) performed on the P-GSK3α and P-GSK3β bands after 
normalizing the intensity with total GSK3α and total GSK3β. (C) SJSA-1 cells were 
infected with lentivirus packaged with plasmid expressing either shRNA against MDM2 
or non specific luciferase as control for 4 days, harvested and analyzed by western 
blotting. Antibody for GSK3α/β phosphorylated at ser 21/9 ( #9331) was from Cell 
Signaling Technologies and GSK3α/β (sc-56913) from SantaCruz Biotechnologies. Other 
antibodies are mentioned in Figure 4. Migration of the proteins are shown by arrows. 
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what we saw with our stable MDM2 expressing H1299. Genes like IKK beta, INOS, IL2 
and IL8 have been shown to be important members of the NF-κB pathway with IKK beta 
phosphorylation activating the pathway and INOS, IL2 and IL8 are targets downstream; all 
of which have been shown to be activated by Akt pathway signaling.(195-197). Ornithine 
Decarboxylase has been shown to be regulated by insulin signaling(198)`. The links 
between PKC alpha and PKC epsilon and the Akt pathway is well studied(199,200).  The 
most significant of our result was the anti apoptotic gene Bcl2, which showed a 96 fold 
increase. BCLxl was also higher, which seemed to imply that the anti-apoptotic pathway 
was activated when MDM2 is induced. Since Bcl2 levels have been shown to be up 
regulated when the Akt pathway is activated(113), this may be the pathway by which 
MDM2 increases Bcl-2 levels. 
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MDM2 induces Bcl-2 expression both at transcriptional and protein levels: Since 
MDM2 offers resistance to chemotherapeutic agents and induces Akt phosphorylation, we 
looked at the proteins which are known Akt targets and have been implicated in drug 
resistance. Bcl-2 has been shown to be induced by Akt phosphorylation(113) and its 
increased levels have been correlated to resistance to Paclitaxel and Etoposide 
resistance(201-204). Our qPCR array result showed that there was a 96 fold increase of 
Bcl-2 transcripts when MDM2 was induced in H1299 cells. Therefore we decided to 
confirm if the same was true in our H1299 cells, stably expressing MDM2. Our results 
show that MDM2 induces Bcl-2 expression both transcriptionally (Figure 25A) and at the 
level of protein (Figure 25B). To further confirm whether endogenous MDM2 plays a role 
in the modulation of Bcl-2 levels, we analyzed SJSA-1 cells stably expressing shRNA 
against MDM2 (Figure 5B) for Bcl2 levels transcriptionally and found that the cells where 
MDM2 was silenced had the Bcl2 expression repressed (Figure 25C). Further we infected 
SJSA-1 cells with lentivirus packaged with plasmids expressing shRNA against MDM2 or 
non specific luciferase for control and harvested the cells after 4 and 5 days for western 
analysis. As shown (Figure 25D), silencing of MDM2 decreases the protein levels of  
Bcl-2. 
Figure24. Induction of MDM2 elevates known Akt targets involved in proliferation, 
migration and chemo resistance pathways: (A) A ponasterone inducible clone was 
harvested after treatment with either 5µg/ml final concentration ponasterone or equal volume 
of vehicle, harvested at 24, 48 and 72 hours after addition of ponasterone and analyzed by 
western blotting. Antibodies used are mentioned in Figure 4 and migration of the proteins 
shown by arrows. (B, C) Normalized fold change in transcript levels of the labeled genes 
determined by qPCR array shown by bar graphs.  An endogenous GAPDH control was used 
to ensure equal mRNA levels in each sample. 
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Figure25. MDM2 induces Bcl-2 expression both at transcriptional and protein levels. 
Normalized fold change in transcript levels of MDM2 and Bcl-2 determined by qPCR is 
shown by bar graphs (A, C).  An endogenous GAPDH control was used to ensure equal 
mRNA levels in each sample. Experiments were conducted as technical triplicates with error 
bars shown indicating standard deviations (B). Experiments have been repeated and show 
similar trend. H1299 stable transfectants expressing MDM2 and control cells were harvested 
and analyzed by western blotting (D). SJSA-1 cells were infected with lentivirus packaged 
with plasmids expressing either shRNA against MDM2 or non specific luciferase for either 4 
or 5 days, harvested and analyzed by western blotting. The antibody for Bcl-2 (610538) was 
from BD Biosciences. Other Antibodies are as in Figure 4. 
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MDM2 induces enhanced processing and increased nuclear localization of NFκB2. 
Gustin et al showed that activation of the Akt pathways induced the processing of the non 
canonical NFκB pathway precursor p100 to p52(205). The processing has been implicated 
in the up-regulation of Bcl-2 and also in cellular processes such as proliferation, migration 
and resistance to chemotherapeutic agents(206-208). Therefore we studied if MDM2 
expressing cells show higher level of NFκB2 processing. Our result (Figure 26A) shows 
that when MDM2 is induced in H1299, it leads to enhanced processing of NFκB2. Since 
NFκB2 is a transcription factor(206-208), we decided to check if we have more processed 
form of the protein in the nucleus when MDM2 is over-expressed. We therefore did a 
cytoplasmic and nuclear extraction of H1299 stable transfectants and looked for the levels 
of processed and unprocessed form of NFκB2. We see (Figure 26B) that there is more 
nuclear localization of NFκB2 when MDM2 is stably expressed. 
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Silencing of NFκB2 sensitizes the MDM2 over-expressing cells to Paclitaxel, but not 
Etoposide treatment.  Since NFκB2 has been implicated in the resistance to 
chemotherapeutic agents(206-208), we tested if our MDM2 over-expressing cells offered 
resistance to Etoposide and Paclitaxel treatment through the NFκB2 pathway. Therefore 
we infected H1299 stable transfectants with lentivirus packaged with plasmids expressing 
shRNA against NFκB2 and silenced the protein levels of NFκB2 (Figure27A). These cells 
were then plated in equal numbers and clonogenic assays were performed to test their 
resistance to Etoposide or Paclitaxel. We observed that that there is no effect in the 
resistance to Etoposide when the NFκB2 in the MDM2 over-expressing H1299 is silenced 
(Figure 27B). However silencing NFκB2 sensitizes the cells to Paclitaxel; the levels of 
NFκB2 in the cell correspond to the survival levels after drug treatment (Figure 27C). 
Therefore it can be concluded that MDM2 offers resistance to Paclitaxel through the 
NFκB2 pathway. 
Figure26. MDM2 induces enhanced processing and increased nuclear localization 
of NFκB2. (A) The ponasterone inducible clone was treated with 5µg/ml ponasterone or 
equal volume of vehicle for 24 hours, harvested and analyzed by western blotting. 
(B)Cytoplasmic and nuclear extracts of the stable H1299 transfectants expressing 
MDM2 or empty vector were made and analyzed by western blotting. β Tubulin is used 
as cytoplasmic marker and Sp1 as nuclear marker. Antibodies for NFκB2 (#05-361) was 
from Upstate Biotechnologies and Sp1 (sc-59 1) from Santa Cruz Biotechnologies. 
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Figure27. Silencing of NFκB2 sensitizes the MDM2 over-expressing cells to Paclitaxel, 
but not Etoposide treatment (A) Stable transfectants of H1299 expressing either MDM2 or 
empty vector were infected with lentivirus packaged with plasmids expressing either shRNA against 
NFκB2 or non specific luciferase. Arrows indicate migration of respective proteins. Clonogenic 
assays performed on NFκB2 silenced cells using (B) 1μM Etoposide or (C) 25nM Paclitaxel. Percent 
survival was calculated considering number of colonies generated in the vehicle treated 
plates to be 100%Experiments done in triplicates and error bars indicating standard deviations are 
shown. 
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Silencing NFκB2 decreases proliferation rate. The NFκB2 pathway has been correlated 
with enhancement of proliferation rates in cells (209). Since we observed increased growth 
rate and more processing of NFκB2 when MDM2 is over-expressed, we decided to test the 
role of NFκB2 in proliferation. We silenced NFκB2 in H1299 cells using siRNA (Figure 
28A) and plated equal number of cells for a growth assay. The result (Figure28B) clearly 
shows that lowering of NFκB2 reduces the growth rate of the cells.  
 
 
 
 
 
 
 
Figure28. Silencing NFκB2 decreases proliferation rate. (A) H1299 cells nucleofected 
with 80 pm siRNA against NFκB2 or non specific scrambled control was harvested 24 hours 
post nucleofection and analyzed by western blotting. (B) Equal number of scrambled RNA or 
siNFκB2 treated H1299 cells were plated 24 hours after nucleofection. The plates were 
harvested every 24 hour post plating and counted using a coulter counter. The experiment 
was conducted in triplicates and error bars are representing standard deviations of the cell 
counts are shown. 
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c. Chapter Summary. To identify the consequence of MDM2 mediated Akt 
phosphorylation, we looked at the players involved in the cell processes mediated by Akt- 
including but not limited to insulin metabolism, proliferation, migration and survival. One 
of the most studied downstream event of Akt phosphorylation is the phosphorylation of 
GSK3. We see enhanced GSK3 phosphorylation in the presence of MDM2 and we show 
that it is mediated by Akt phosphorylation. Also silencing MDM2 reduces the 
phosphorylated GSK3 levels. A broad idea of the consequence of MDM2 over-expression 
is demonstrated by the qPCR array we performed using cDNA prepared from an inducible 
MDM2 system. The resulting modulation of genes, which have been shown to be involved 
in the Akt pathway, reinforces our observation of MDM2 mediating the expression of the 
Akt pathway. Further we show that stable MDM2 over-expressing cells have increased 
transcription and protein levels of anti apoptotic Bcl2. Also silencing endogenous MDM2 
leads to reduction in Bcl2 levels. Bcl2 levels have been correlated with Akt 
phosphorylation and resistance to drugs like Etoposide and Paclitaxel. This could be a 
mechanism of drug resistance in MDM2 over-expressing cells due to increased Akt 
phosphorylation. Further investigation is required at this point. We also demonstrate the 
ability of MDM2 to increase processing and nuclear translocation of NFκB2. By silencing 
NFκB2, we show that the Paclitaxel resistance offered by MDM2 is diminished and this 
therefore being the route through which MDM2 increases resistance to Paclitaxel. Finally, 
we show the role played by NFκB2 in proliferation, thus providing a plausible mechanism 
of MDM2 mediated increased proliferation. 
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M. Discussion: 
  MDM2 over-expression occurs in nearly 7% of all cancer types(15). Biochemical and 
genetic studies have shown a relationship between MDM2 over-expression and cancer 
development. MDM2 is also used as a prognostic marker in the clinic and is an important 
target for anti cancer drug development(133). However no significant treatment strategy 
has been identified in cancers where MDM2 is over-expressed.(141) Most of the studies 
involving MDM2 attribute its oncogenic potential to its ability to bind with and degrade 
the tumor suppressor p53.  However MDM2 has p53 independent activities and it has been 
shown to be oncogenic in permissible environments(54). This leads to the question of what 
mechanisms are employed by this oncogene towards oncogenesis.  
A lot of recent work has shown the involvement of MDM2 with the mitogenic signaling 
pathways. MDM2 has been shown to be phosphorylated by Akt at Serine 166,186 and 
188(67,85,86). This event results in the nuclear translocation of MDM2 and further 
binding and degradation of p53; phosphorylation of MDM2 by Akt is thought to be 
necessary for degradation of p53 and a mechanism of oncogenesis. MDM2 is known to 
shuttle between the nucleus and cytoplasm and has also been shown to have activities 
outside the nucleus. Examples of this include degradation of  cell surface receptors like 
IGFR(68), Androgen receptor(81) by MDM2, binding to and degrading signaling 
molecules like GRK-2(70) and β Arrestin (69). The current thinking behind these activities 
of MDM2 is that after nuclear entry and its interaction with p53, MDM2 gets exported out 
of the nucleus and the excess MDM2 is available for the above interactions(69,70). 
However, there is no study to indicate the sequence of events when the cell lacks p53. 
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Although much has been done to show the role of activated Akt pathway in the nuclear 
entry of MDM2, there is no explanation for situations in which there is over-expression of 
MDM2 in the cell. We have observed that a transient over-expression of MDM2 shows 
most of the expression within hours of transfection, reaching a peak at about 8 hours and 
then the levels going down. It has been suggested that MDM2 protein levels are regulated 
by self-ubiquitination, which happens after nuclear entry and subsequent export. An 
intuitive suggestion would be that enhanced levels of Akt activation would be required for 
phosphorylation of the increased pool of MDM2 to facilitate its nuclear entry, which 
precedes its export. This scenario is depicted in Figure 29, 
 
 
 
 
Figure29. MDM2 and Akt phosphorylation. (A) The interaction of MDM2 and 
phosphorylated Akt results in the phosphorylation of MDM2 and subsequent nuclear entry. 
(B) When MDM2 is over-expressed, the pool of phosphorylated Akt will be used up to drive 
the nuclear entry of MDM2, and the unphosphorylated MDM2 which remain in the cytosol 
may demand for increased Akt phosphorylation. 
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Our observation that MDM2 mediates Akt phosphorylation represents a novel signaling 
event. Both cancer cell lines and normal diploid fibroblasts show enhanced Akt 
phosphorylation when MDM2 is over-expressed and silencing of endogenously over-
expressing MDM2 in cancer cell lines reduces the Akt activation. Also importantly, this is 
an event that is independent of two of the most important tumor suppressors- p53 and 
pTEN, as H1299 cell lines lacks p53 and has suppressed PTEN expression(210,211).  
We observed that MDM2 over-expressing cells could offer enhanced chemo resistance to 
drugs used in the clinical setting against various cancer subtypes. Several mechanisms 
have been put forth to explain the possible role for MDM2 in decreasing response to 
chemotherapy. Besides the most well known ability to degrade p53 and therefore reduction 
in apoptosis and cell cycle arrest, MDM2 has been shown to increase the expression of the 
Multidrug Resistant gene (mdr1) atleast in glioblastoma cell lines(212). Other groups have 
shown the ability of MDM2 to increase p65 expression and therefore cause Doxorubicin 
resistance(80). Here we show that by inhibiting the Akt phosphorylation we can sensitize 
MDM2 over-expressing cells to treatment by Etoposide. Since there is no treatment 
strategy available at present when MDM2 over-expression is used as marker, targeting the 
Akt pathway in these tumors could be pursued as a viable treatment technique. Also 
whereas most of the current work focusing on small molecule inhibitors, peptide blockers 
and RNA interference against MDM2 has been shown to induce the apoptotic cell death in 
normal cells, targeting the Akt pathway has been shown to be more specific(213). If more 
data is generated in this scheme, we will be able to have a clearer picture on this treatment 
strategy and work on its short comings.  
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We also show that inhibition of Akt phosphorylation serves to counter the enhanced 
proliferation rate in cells over-expressing MDM2.  Further we show that MDM2 
expressing cells have increased migration ability. Since the cell processes of increased 
proliferation, migration and chemo resistance are properties that define the nature of cancer 
cells, it seems to suggest that MDM2 mediated oncogenesis could occur through the 
activation of the Akt pathway. 
Towards finding a mechanism of Akt activation by MDM2, we studied the importance and 
requirement of the PI3K pathway and found that inhibition by wortmannin can inhibit the 
Akt phosphorylation by MDM2. Also we see enhanced IGF-1 signaling occurring when 
cells over express MDM2 and when endogenous over-expressed MDM2 is silenced, it 
reduces the IGF-1 signaling pathway. Since the IGF-1 has been shown to activate Akt 
through the PI3K pathway(169-172), this suggests that MDM2 mediated Akt 
phosphorylation happens through the PI3K pathway. Also it suggests that MDM2 may be 
augmenting some factor in the signaling pathway, since silencing MDM2 reduces the 
signaling mechanism. However there is no change in the levels of Threonine 308 
phosphorylation by MDM2 which may be a counter argument for the role of the PI3k 
pathway(100,101,163,164,173). This may be explained in terms of the deregulation of the 
PDK1 in H1299, which serves to phosphorylate Akt at Threonine 308 or some other 
member in the pathway. Further investigation is required for a more substantial answer. 
Another supporting evidence for the role of the PI3K pathway comes from our observation 
that Rictor, a kinase which has been shown to phosphorylate Akt at Serine 473 residue 
specifically(99) does not play any role in MDM2 mediated Akt activation. Also there is no 
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change in transcript levels of PHLPP, a phosphatase specific for serine 473 
residue(106,107) and CTMP, a protein that binds to Akt and dephosphorylates it(109). It 
should be taken into consideration that Akt phosphorylation at serine 473 can be performed 
by other cellular kinases like ILK(100-102), DNA-PK(104) when there is DNA damage as 
well as other, still debatable  kinases. A more definite answer would require substantial 
work to be done for the proper mechanism to be charted out. An additional insight on the 
mechanism can be got from the ability of MDM2 to increase transcript levels of CXCL8 or 
IL8. This has been shown to be able to activate the Akt pathway. Also it falls in place with 
our migration data(177). This needs further investigation and could prove to be the 
mechanism. 
MDM2 has been shown to interact with a wide variety of proteins in the cell and modulate 
their expression and thereby cellular processes. These interactions have been mapped to 
the various domains of MDM2 and have served the purpose of providing valuable clues in 
identifying the properties of MDM2 and their mechanism(54,166). Our domain analysis 
resulted in the identification of a domain stretching from amino acids 189-220, which has 
been shown to be the region where MDM2 and phosphorylated Akt interact(86), to be 
responsible for our observation. The domain analysis also allowed us to negate the 
possibility of our observation to be caused by one of our previous observations in the 
laboratory- MDM2’s interaction with Elongation Factor EF1α. This interaction required 
two domains lying between amino acids 1-58 and another between amino acid 221-
325(82) and MDM2 mediated Akt phosphorylation does not seem to require the first 154 
amino acids at least. Also we showed that deletion mutants able to induce phosphorylation 
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of Akt, increase resistance to Etoposide and inhibition of the Akt phosphorylation in these 
mutant expressing cells, sensitizes them to drug treatment similar to what we see with full 
length MDM2. 
In trying to figure out the consequences of MDM2 mediated Akt phosphorylation, we 
looked at one of the most frequently studied downstream target of Akt phosphorylation, 
GSK3(126-128,180,181) and found that MDM2 expressing cells express higher levels of 
phosphorylated GSK3α and β. These levels can be reduced by using an inhibitor targeting 
Akt, thus proving the importance of the elevation of Akt activation towards increasing 
phosphorylated GSK3 levels. Also silencing endogenous levels of MDM2 in over-
expressing cell lines reduces the GSK3 phosphorylation. We also did a qPCR array to 
identify some of the targets, shown to be involved in the Akt pathway that get modulated 
by MDM2 induction in an ponasterone inducible clone. Our result showed changes in 
expression of genes which have been identified to be important in processes of 
proliferation, migration, apoptosis resistance, chemotherapeutic resistance among others. 
The most significant changes were shown by genes which controlled apoptosis with 
Bcl2(113), an anti apoptotic factor showing nearly 96 fold increase. Therefore we validated 
this result and saw that MDM2 over-expressing cells indeed expressed higher transcript 
and protein levels of Bcl2.  Also, silencing of MDM2 reduced Bcl2 levels. Consistent with 
the ability of activated Akt to induce processing of NFκB2(205), we observed that MDM2 
over-expressing cells had higher levels of processed NFκB2. Also we show that MDM2 
over-expressing cells have higher nuclear localization of NFκB2. This is important because 
NFκB2 is a well known transcription factor and has been shown to activate genes 
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responsible for proliferation, migration, and drug resistance and anti apoptosis including 
Bcl-2(206-209,214). Towards finding the role of NFκB2 in MDM2 mediated chemo 
resistance; we did clonogenic assays after silencing NFκB2 and present evidence that the 
MDM2 mediated Paclitaxel resistance goes through the NFκB2 route. However lowering 
of NFκB2 does not compromise MDM2 mediated resistance to Etoposide. Further work 
will be required to elucidate the exact mechanisms of drug resistance to Etoposide and 
Paclitaxel and it will be interesting to figure out the distinct pathways by which MDM2 
provides resistance to various chemotherapeutic agents.  
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N. Experimental Methods. 
Plasmids and siRNA: The MDM2 cDNA was a generous gift from Bert Vogelstein(Johns 
Hopkins University Medical Institutions, Baltimore, MD)(215).Construction of plasmids 
expressing full-length MDM2 and its deletion mutants has previously been described in 
detail ((45,47)). Plasmids (pLKO.1) expressing short hairpin (sh) RNA against MDM2 and 
NF-κB2 from U6 promoters and harboring puromycin resistance gene were purchased 
from Open Biosystem.  The control plasmid expresses shRNA against non-endogenous 
luciferase gene. Plasmid (pLKO.1) expressing short hairpin (sh) RNA against Rictor from 
U6 promoter, Rictor-1 was purchased from Addgene. The Short interfering (si) RNA 
,siGENOME SMARTpool reagent M-003279-02-0005, directed against human MDM2 
(MDM2 siRNA) was purchased from Dharmacon, si RNA against NFκB2 (duplex of 5’-
rgrCrCrCUrgrArgUrgrCrCUrgrgrAUrCU TT-3’ and 5’rArgrAUrCrCrArgrgrCrArgrgrgr 
TT-3’)  and control scramble RNA ( duplex of 5’- 
rCrAUrgUrCrAUrGUrgUrCrArCrAUrCUrC TT  -3’ and 
5’rgrArgrAUrgUrgrArCrArCrAUrgrArCrAUrG TT-3’) was designed using a program 
suggested by Qiagen Inc, and was purchased from Proligo. 
The pINDβglobin intron MDM2 used for generating the inducible clones was generated by 
restriction digestion of the pINDβglobin vector (Invitrogen)using BamH1 and ligating it 
with the MDM2 cDNA. This clone was designated the pINDβglobinMDM2. 
Cells, transfections and generation of stable transfectants: H1299, MCF10A and WI38 
cells were purchased from American Type Culture Collection and were maintained in 
media as suggested by the suppliers. SJSA-1 cell line was a kind gift from A.T. Look 
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(216). HEK 293T cells was a kind gift from Dr Qui Y (University of Maryland) For 
nucleofection, cells were seeded 48 to 72 hours before transfection. Cells were then 
trypsinized, and a suspension of 3X106 cells was mixed with plasmids or siRNA and 
pulsed (nucleofected) using a Nucleofector and kit reagents (Amaxa) following supplier’s 
protocol and plated in 10cm culture dishes in normal growth media. To generate MDM2 
stable transfectants, H1299 cells were lipofected with MDM2 expression plasmids (full-
length or deletion mutants) or vector plasmid harboring neomycin resistance gene using 
lipofectamine 2000 reagent( Invitrogen) as per manufacturer’s protocol. The cells were 
pooled and selected using 100μg/ml of G418 (GibcoBRL). To generate stable transfectants 
expressing MDM2 shRNA, SJSA-1 cells were transfected with pLKO.1 plasmids 
expressing MDM2 shRNA or luciferase shRNA by nucleofection. Nucleofected cells were 
selected with pooled and selected using 2μg/ml puromycin (Invivogen).  Several MDM2 
shRNA expression plasmids were tested to select expression vectors efficiently silencing 
MDM2 expression. 
Antibodies: Antibody against MDM2 (IF-2) from Calbiochem or N-20 (SC813 ) from 
Santa Cruz was used in 1:100 dilutions. 2A10 antibody was a gift from Arnold Levine and 
was used at 1:200 dilutions. Antibody against, Akt phosphorylated at Ser473 (#9271) and 
Thr 308(#9275), Rictor (#2114), GSK3α/β phosphorylated at ser 21/9 ( #9331) were 
purchased fromCell Signaling and used as per manuufacturer’s instructions., β-actin 
antibody (AC-15)  was purchase from Sigma and used at 1:5000 dilution, CDK4 antibody 
Ab-2 was purchased from Calbiochem and used at 1:1000 dilution. Akt (sc-8312), 
GSK3α/β (sc-56913), Sp1(sc-59 1)and GAPDH (sc32233) was purchased from Santacruz 
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Biotechnology and used at 1:1000 dilution, NF-κB2 (#05-361) was purchased from 
Upstate Biotechnology and used at 1:5000 dilution, pERK(V-8031) was purchased from 
Promega and Bcl2 (610538 ) from BD biosciences and used as per manufacturer’s 
protocol.  
Western Blot Analysis: Cells were washed with ice-cold phosphate buffered saline (PBS) 
and harvested in a cell lysis buffer (Promega) containing 50 mM NaF, 0.1M 
phenylmethylsulfonyl fluoride, Na pyrophosphate, Na orthovanadate and protease 
inhibitors as described previously (9, 18). The lysate was boiled for 5 minutes in 4X 
lamellae loading buffer dye (50 mM Tris-HCl pH 6.7, 2% SDS, 2% β-mercaptoethanol, 
and bromophenol blue) and analyzed by SDS-polyacrylamide gel electrophoresis, followed 
by Western blot analysis using respective antibodies ((217)). 
For westerns involving detection of phosphorylated Akt, the plates were washed with ice 
cold PBS once and harvested in 1 ml ice cold PBS by scrapping into tubes. They were 
spun at 990g, 10 mins,4 OC and  the pellets treated with lysis buffer consisting of187.5mM 
Tris-HCl(pH6.8 at 25OC), 6%w/v SDS, 30% Glycerol, 150mMDTT and 0.035 w/v 
bromophenol blue and sonicated for 15 secs,( 5 secs on, 2secs off pulses) at out put of 3 in 
a Misonix 3000 sonicator using a microtip. The tubes were spun down, boiled and 
analyzed by SDS-polyacrylamide gel electrophoresis using a 10% acrylamide gel, 
followed by Western blot analysis using respective antibodies. 
Inhibitors and chemotherapeutic drugs:  Wortmannin (Upstate Biotechnology) 
treatments were carried out at a concentration of 100 nM for 4 hours ((121,218)  ). Akt 
inhibitor SH-6 (AKT III) (Calbiochem) was used at a concentration of 1.76 μM for 4 
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hours. After pretreatment, cells were either harvested for Western blot analysis or plated to 
determine drug sensitivity by colony formation assay.  IGF-1 (#I3769) was purchased from 
Sigma and used at 50ng/ml final concentration. Etoposide, Carboplatin and Paclitaxel were 
purchased from Sigma and used at appropriate concentrations. 
Determination of drug sensitivity by colony formation assay: Colony formation assay 
was performed as reported earlier (219). Cells were seeded at equal density in 10-cm plates 
in triplicate and treated with chemotherapeutic drugs at specified concentration or the 
vehicle for 48 hours.   Cells were then grown in normal growth media to allow colony 
formation by viable cells. After generation of colonies cells were fixed with methanol, 
stained with methylene blue and colonies were counted.  
Growth Assay: Cells were seeded at a density of 1X104 cells per 60-mm plate. Fifteen 
plates of each line were plated initially. Whenever needed three plates of each was 
trypsinized and cells were suspended in 1 ml of serum containing medium. Cells were 
counted using a Beckman Coulter Counter and the total number of cells calculated and 
plotted. Media in the remaining plates were changed every day. Standard deviations were 
calculated from the three individual experiments run simultaneously. 
Lentivirus generation and infections: Lentiviral production was done by co-transfection 
of pDelta8.7 backbone, pVSVG and the pLKO.1 vectors expressing the shRNA into 293T 
cells by calcium phophate transfection(220). The media was harvested after 48 h and 
aliquoted. It was subjected to flash freezing and further storage at -80 OC.  
Cells were seeded at a density of 2X105 in 10cm plates, 24 hours prior to the infection. For 
infection, the media was removed and the cells were washed once with Hanks Balanced 
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Salt Solution. The frozen virus was thawed quickly and added to the plates. The plates 
were rocked every 15 minutes by hand and incubated at 37 OC. After 2 hours fresh media 
containing 10%serum was added and kept in the incubator at 37 OC, 5%CO2. 
Migration assay: For the scratch assay, cells were trypsinized using 0.1% trypsin-2.21mM 
EDTA (Mediatech, Herndon, VA) and plated in triplicate in a 12-well cell culture plate 
(Greiner Bio-One, Monroe, NC) and incubated at 37° C until cells were completely 
confluent.  At this time, a sterilized pipette tip was placed within each well and scratched 
across the surface of the plate removing the complete layer of cells within the scratch area.  
Following cell removal, each well was washed once with PBS and then replaced with 
medium.  Immediately following, the width of the scratch was measured at a specific point 
under a 5x objective using a light microscope and AxioVision software.   Cells were then 
returned to a 37° C incubator.  Cells were incubated for a total of 20 h, at which time the 
scratch width was measured again using the same procedure and at the same position as in 
time 0.  
Indicible clone generation: Ponasterone inducible clones were generated as per 
manufacturer’s protocol (Invitrogen). Briefly, H1299 cells were plated one day previous to 
the transfection in a 6well plate. The next day, co transfection was conducted on these cells 
with pvgRXR (Invitrogen) and the pINDβglobinMDM2 using 
Lipofectamine2000(Invitrogen) using manufacturer’s protocol. After 24 hours the cells 
were trypsinized and re-plated in a10cmplate and selected using 100μg/ml G418(Gibco) 
and 25μg/ml Zeocin(Invitrogen).Clones were then picked and allowed to undergo further 
selection and grow and analyzed by induction with 5μg/ml Ponasterone A(Invitrogen).  
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RNA extraction Generation of cDNA and quantitative PCR (QPCR):Total RNA was 
isolated from exponentially growing cultured cell lines using TRIzol reagent (Life 
Technologies, Invitrogen) following a protocol supplied by the manufacturer. Quality of 
RNA was checked by 2% agarose Tris-borate-EDTA gel electrophoresis.  cDNA was 
synthesized using the Thermoscript reverse transcription- PCR system (Invitrogen). 
QPCR was performed using a LightCycler system (Roche). Primers were designed using 
OLIGO 5 software (Molecular Biology Insights) and were synthesized by Sigma 
Genosys(MDM2, GAPDH) or IDT(CTMP,PHLPP). Reactions were performed in 
triplicate utilizing SYBR green dye, which exhibits a higher fluorescence upon binding 
of double-stranded DNA.  The methods have been described previously (219). The 
QPCR primers used were as follows: 
(a) MDM2, 5’- CCC AAG ACA AAG AAG AGA GTG TGG- 3’ and 5’- CTG GGC 
AGG GCT TAT TCC TTT TCT- 3’;  
(b) GAPDH, 5’-GTC AAC GGA TTT GGT CGT ATT-3’ and 5’- GAT CTC GCT CCT 
GGA AGA TGG-3’,  
(c) CTMP,5’-CTAAGACTGCTCTTTGACCAG 3’ and 5’-
CTCCATGAATGAATCCAGGT-3’ 
(d) PHLPP, 5’ CACCCCATCTGTCTGTCCA3’ and 
5’GCTGCTGTTTCTCCTTCTCC3’. 
(e) Bcl2, 5’- CAACATCGCCCTGTGGAT-3’ and 5’ 
GCCAAACTGAGCAGAGTCTTC3’ 
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(f) CXCL8, 5’-TTTTGCCAAGGAGTGCTAAAG-3’ and 5’-
AACCCTCTGCACCCAGTTTTC-3’ 
(g) Actin, 5’-CATGTACGTTGCTATCCAGGC-3’ and 5’-
CTCCTTAATGTCACGCACGAT-3’. 
PCR-Array: The Ponasterone inducible clone cells were induced for 24 hours and RNA 
extracted and cDNA generated as mentioned earlier PCR was performed in a Human 
Signal Transduction Pathway Finder RT2 ProfilerTM  PCR Array(SuperArray Bioscience 
Corporation) in a ABI Prism 7500 Sequence Detector (Applied Biosystems). For data 
analysis the ΔΔCt method was used; for each gene fold-changes were calculated as 
difference in gene expression between induced and uninduced cells. 
Preparation of cytoplasmic and nuclear extracts:  Cyotosolic and nuclear extracts were 
prepared following a method by Mendez and Stillman (221) Cultured cells were harvested 
by trypsinization, washed with phosphate buffered saline and were resuspended in a buffer 
A containing 10 mM HEPES (ph 7.9), 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10% 
glycerol, 1 mM DTT, 1X protease inhibitor (Calbiochem), and 0.1 mM PMSF (phenyl 
methyl sulfonyl fluoride, Sigma).  Cells were lysed by addition of Triton X-100 to a final 
concentration 0.1%, and incubating on ice for 5 minutes.  Nuclei were collected by low 
speed centrifugation (4 min, 1,300g, 4˚C).  The supernatant were further clarified by high-
speed centrifugation (12,000g, 4˚C).  The nuclear pellet was washed in buffer A and then 
lysed in a buffer B (3 mM EDTA, 0.2 mM EGTA, 1mM DTT and protease inhibitors as 
described above.  Insoluble chromatin fraction was collected by centrifugation (4 min, 
1,700g, 4˚C), washed once with buffer B, suspended in Laemmli loading buffer and 
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sonicated for 30secs(5secs on and 1 sec off pulse) at output of 3.5 using a Misonix 3000 
sonicator using a microtip  
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